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ABSTRACT 
TIFFANY L THAI:  Functional Characterization of ADP Ribosyl Cyclase Signaling 
Pathways in the Renal Microcirculation  
(Under the direction of William J. Arendshorst, PhD) 
  
 Due to its role in the regulation of salt and water balance, the kidney is thought to be 
the primary organ involved in arterial blood pressure regulation.  The mechanisms governing 
contraction of renal resistance arteries/arterioles are incompletely understood, however.  The 
purpose of my dissertation was to investigate the importance of a novel signaling pathway 
involving the enzyme ADP ribosyl (ADPR) cyclase in the regulation of calcium (Ca2+) 
signaling in afferent arterioles and regulation of renal vascular resistance. 
 Physiological measurements of renal blood flow (RBF) were performed on 
anesthetized rats before, during, and after pharmacological blockade of ADPR cyclase and its 
downstream target, the ryanodine receptors (RyR).  Inhibition of ADPR cyclase under basal 
conditions resulted in a significant increase in RBF, and impairment of ADPR cyclase or 
RyR function attenuated RBF responses to the vasoconstrictors angiotensin II (Ang II), 
norepinephrine (NE), and endothelin-1 (ET-1) by 30-50%.  Further analysis revealed that 
ADPR cyclase and RyR contribute to vasoconstrictor responses induced by either ET 
receptor, ETA or ETB. 
 Measurements of cytosolic Ca2+ concentration ([Ca2+]i) in isolated rat afferent 
arterioles revealed that the second messenger nicotinic acid adenine dinucleotide phosphate 
(NAADP) participated in the actions of NE and ET-1.  [Ca2+]i transients produced by either 
agonist were 
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diminished by at least 50% in the presence of disruption of lysosomal Ca2+ or NAADP 
receptor inhibition. 
 Real time quantitative RT-PCR studies on isolated mouse preglomerular resistance 
arterioles determined mRNA expression of ADPR cyclase family members CD38 and 
CD157.  Genetic knockout of CD38 resulted in attenuated RBF responses to Ang II, NE, and 
ET-1.  Pharmacological blockade of ADPR in CD38-/- animals resulted in no significant 
attenuation of Ang II-induced renal vasoconstriction, suggesting that CD38 functions as the 
predominant ADPR cyclase. 
 Overall, these studies provide evidence for the physiological function of ADPR 
cyclase, its second messengers, and downstream effectors in the regulation of renal 
hemodynamics.  Further investigation of this pathway in the renal vasculature will result in a 
deeper understanding of renal hemodynamics. 
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A. ROLE OF THE RENAL VASCULATURE IN BLOOD PRESSURE 
REGULATION. 
 Inside the kidney lies a vast network of tubules and blood vessels designed to 
efficiently regulate the volume and composition of plasma and extracellular fluid, thus 
playing a crucial role in determining arterial pressure.  Blood flows into the kidney through 
the renal artery and travels through the preglomerular vasculature consisting of interlobar, 
arcuate, and interlobular arteries before entering the afferent arteriole and glomerulus.  In the 
glomerulus, ultrafiltration occurs as fluid passes through hypothetical pores of glomerular 
endothelial cells, collagen and glycoproteins of the basement membrane, and slit-pores of 
podocytes of Bowman's capsule (which may have a filtration function in addition to laying 
down basement membrane) (133; 244).  Post-glomerular efferent arterioles hold blood 
containing high concentrations of blood cells, proteins, and other un-filterable substances.  
Efferent arterioles branch to form the cortical peritubular capillaries and medullary vasa recta 
where blood becomes de-oxygenated before returning to the venous circulation.  The state of 
contraction and relaxation imparted by the pre- and post-glomerular resistance vessels 
determine glomerular capillary hydrostatic pressure and the rate of fluid flow through the 
glomerulus, into Bowman's space, and into the proximal tubule where the reabsorption and 
secretion of electrolytes is initiated to maintain plasma volume and electrolyte composition. 
 Fluid flows through the proximal tubule where cells covered in luminal microvilli 
reabsorb 67% of the filtered salt and water and virtually all glucose and amino acids, past the 
“leaky” cells of the descending limb of the loop of Henle that allow free passage of water and 
solute and the “tight” cells of the ascending limb that prevent water reabsorption.  
Reabsorption of solute without water sets the gradient for “free” water reabsorption at more 
3 
 
distal nephron sites that are sensitive to anti-diuretic hormone (vasopressin).  Tubular water 
permeability regulated by hormone-sensitive aquaporin-2 favors the formation of 
concentrated or dilute urine depending on hydration state and the plasma level of anti-
diuretic hormone.   Fluid leaving the thick ascending limb of Henle is presented to the 
macula densa, part of the juxtaglomerular apparatus important as a signal sensor for 
tubuloglomerular feedback and control of preglomerular vascular resistance.  After the distal 
tubule fluid enters the collecting duct where aldosterone dictates the amount of salt 
reabsorbed by principal cells and intercalated cells determine pH.  Atrial natriuretic hormone 
favors sodium excretion by inhibiting epithelial sodium channels (ENaC) along the 
medullary collecting duct.  Fluid leaving the collecting ducts passes out through the papilla 
and into the pelvis, ureter and bladder for excretion. 
 Whereas the loop of Henle and vasa recta in the renal medulla are primarily 
responsible for fluid concentration, the afferent arteriole is primarily responsible for 
determining the glomerular filtration rate and fluid flow entering through the tubules.  
Regulatory factors affecting afferent arteriolar resistance include neural and hormonal 
systems and paracrine / autacrine substances (180).  In addition, this action of the afferent 
arteriole occurs as a myogenic response to the hydrostatic pressure in the afferent arteriole 
and as a tubuloglomerular feedback response to the composition in the distal tubule and is 
termed autoregulation (180).  
 Autoregulation was first observed in the kidney in the 1930s upon the observation 
that blood flow remains constant despite changes in perfusion pressure over a defined 
pressure range (125; 258; 102). Currently, two mechanisms of autoregulation are generally 
accepted:  a rapid myogenic response and more delayed tubuloglomerular feedback (TGF) 
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(43).  The myogenic response is an inherent property of VSMC of resistance arterioles that 
causes the vessels to constrict in response to increases in pressure/distension/stretch since 
isolated perfused afferent arterioles respond to mechanical stretch by constricting (158).  
Since myogenic response is flow- independent, it has been presumed that wall tension or 
hoop stress is the primary signal (92), however this has yet to be determined.  Whatever the 
initiating factor, VSMC in the wall of the preglomerular arteries/arterioles depolarize in 
response to an increase in luminal pressure to activate L-type Ca2+ channels and produce  
vasoconstriction (see section C).   
 A second, slower autoregulatory mechanism also exists.  The anatomy of the nephron 
is such that the macula densa region at the end of the thick ascending limb of Henle’s loop 
(and also cortical collecting duct) touches the parent afferent arteriole.  As a result of this 
anatomy, TGF can occur to regulate blood flow and glomerular function.  Modified epithelial 
cells called macula densa sense the composition of tubular fluid (44).  Signals of tubular 
origin are transduced to the afferent arteriole to alter vessel tone and thus regulate RBF and 
GFR.  It is generally accepted that Na+, K+, and Cl- concentration or load delivered  in the 
tubular fluid are sensed by the Na+/K+/2Cl- transporter (NKCC2) located in the luminal 
membrane of macula densa cells (98).  In response to increased electrolyte transport, macula 
densa cells produce varying levels of adenosine and/or ATP (29).  VSMC of afferent and to a 
lesser extent, efferent arterioles possess a family of purinergic receptors (A1 receptors for 
adenosine or P2X1 receptors for ATP) that respond to ATP and adenosine to produce 
vasoconstriction (245). 
 Recent data suggest that third and fourth autoregulatory mechanisms may also exist.  
What is currently known as the third autoregulatory mechanism has been identified by three 
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groups of investigators and is slower than the myogenic response and TGF (128; 130) and 
has been characterized as very low frequency (224).  Very recently animals lacking A1 
adenosine receptors were given the NKCC2 inhibitor furosemide to reveal a fourth possible 
autoregulatory mechanism (131).  Since the putative fourth mechanism shares a time course 
with TGF, however, it may simply represent a previously unidentified component of TGF 
that is independent of both A1 receptors and NKCC2. 
 The volume and composition of blood entering the kidney directly impacts sodium 
excretion and blood volume.  Changes in GFR imparted by alterations in afferent and 
efferent arteriolar tone determine the amount of sodium passing into the proximal tubule and 
thus the amount of sodium reabsorbed.  In addition, afferent arteriolar contraction and 
relaxation increases and decreases cortical blood flow.  Since proximal and distal tubular 
sodium reabsorption occurs largely by diffusion, changes in cortical blood flow impact 
reabsorption in these segments (138).  Efferent arteriolar tone determines medullary blood 
flow.  This impacts reabsorption by proximal tubules of deep nephrons.  In addition, it is 
thought that equilibration of the fluid in the descending limb of Henle’s loop with the blood 
in the vasa recta of juxtamedullary nephrons is a necessary step in urine concentration.  Thus, 
efferent arteriolar tone directly influences urine concentration 166; 203). 
B. REGULATION OF VASCULAR TONE. 
 Due to the importance of renal resistance arteriolar diameter in governing (GFR and 
systemic AP, the mechanisms dictating the contractile state of these vessels has been the 
subject of a great deal of research.  The basic cellular mechanisms of VSMC contraction are 
similar in systemic arteries and renal microvessels, with the bulk of the contractile response 
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relying on the regulation of cytosolic calcium concentration ([Ca2+]i).  VSMC work together 
with underlying endothelial cells (EC) to dictate arteriolar tone, and [Ca2+]i is a key 
regulatory factor in both cell types.  In VSMC, [Ca2+]i binds to calmodulin (CaM), leading to 
the activation of myosin light chain kinase and phosphorylation of myosin light chain.   This 
alters the conformation of myosin such that the heads bind actin filaments and cause cellular 
contraction.  Myosin light chain kinase is also regulated by myosin light chain 
phospohrylase, an enzyme that dephosphorylates and inactivates the kinase.  Myosin light 
chain phosphorylase is, in turn, inhibited by phosphorylation by Rho kinase(43).  In EC, on 
the other hand, [Ca2+]i activates endothelial nitric oxide synthase, leading to production of 
nitric oxide (NO), a potent vasodilator(76).  NO diffuses rapidly into nearby VSMC, 
activating guanylyl cyclase and increasing production of cyclic GMP.  Cyclic GMP then 
produces VSMC relaxation by three main mechanisms:  1) directly inhibiting Ca2+ entry 
through store-operated Ca2+ channels, 2) stimulating large-conductance Ca2+-activated K+ 
channels (BKCa) and K+ efflux to produce plasma membrane hyperpolarization, thus 
inactivating voltage gated Ca2+ channels, and 3) increasing activity of cGMP-dependent 
protein kinase, an enzyme that phosphorylates and activates myosin light chain phosphatase 
leading to the dephosphorylation of MLCK (28). 
 Due to the importance of Ca2+ in vasomotor tone, VSMC have evolved a variety of 
different signaling pathways regulating a plethora of Ca2+ channels.  These channels can 
cause global increases in [Ca2+]i to produce vasoconstriction or a small subset of channels 
can act locally to produce small increases in localized Ca2+ called “sparks” that influence a 
variety of signals in subcellular domains.  [Ca2+]i is increased primarily via two general 
mechanisms:  entry from outside via plasma membrane channels and release or mobilization 
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from sarcoplasmic reticular (SR) stores maintained by the sarcoplasmic/endoplasmic 
reticulum ATPase (SERCA).   
 Three families of Ca2+ channels exist in the plasma membrane:  voltage-gated Ca2+ 
channels whose activities depend on the plasma membrane potential, and two classes of 
voltage-independent channels:   receptor-operated Ca2+ channels (ROC) that are directly 
activated by G protein-coupled receptors (GPCR), and store-operated Ca2+ channels (SOC) 
that open in response to depletion of SR Ca2+ stores.   Of the voltage-gated Ca2+ channels, 
three are known to be present in renal microvessels.  L-type and T-type channels exist on 
both afferent and efferent arterioles (101) whereas P/Q type vessels are found only on 
afferent arterioles (104). 
 L-type channels have been implicated in the regulation of basal afferent arteriolar 
tone and responses to ATP, Ang II, norepinephrine (NE), vasopressin, and endothelin-1 (ET-
1) (118; 141; 193). Inhibitors of L-type channels preferentially dilate the afferent arteriole, 
suggesting a minor role for L type channels in the regulation of basal efferent arteriolar tone 
(26).  L-type channels in the efferent arteriole may be activated by aldosterone (7) or by 
inhibition of nitric oxide synthases (71).  In the afferent arteriole, depolarization caused by 
cell stretching, nerve stimulation, or activation of GPCR on VSMC increases the probability 
of opening of the L-type channel to allow Ca2+ influx (85; 13). 
 More recently, T-type voltage gated Ca2+ channels have been shown to participate in 
the regulation of basal tone and in Ang II-induced constriction of both afferent and efferent 
arterioles.  Inhibitors of T-type channels produce efferent and afferent arteriolar dilation 
(103; 70) and attenuate constrictor responses to Ang II (72) in an isolated perfused 
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hydronephrotic kidney model.  The constrictor effect of T-channel activation is thought to be 
mediated by release of Ca2+ from SR stores since T channel inhibitors have no effect on Ang 
II responses in the hydronephrotic kidney model in the presence of inhibition of SERCA by 
thapsigargin (103).   
 P/Q type voltage-gated Ca2+ channels have also been identified in afferent arterioles, 
but the exact function and importance of these channels remain a mystery (104).  One study 
has shown that inhibition of a subunit of P/Q type voltage gated Ca2+ channels attenuates 
[Ca2+]i and contractile responses to depolarization in isolated afferent arterioles (100). 
 A family of plasma membrane transient receptor potential channels (TRP) are 
currently emerging as important regulators of [Ca2+]i in renal microvessels.  TRPC 1,3,4,5, 
and 6 have been identified in preglomerular resistance arterioles (56), with 3 and 6 being 
most abundantly expressed.  TRPV4, TRPV5, and TRPM7 are expressed at very high levels 
in whole kidney homogenate, but the exact location of these channels is unknown (142).  In 
addition, TRPC6 stimulation results in increases in [Ca2+]i in renal afferent arterioles, 
suggesting a possible physiological function for this channel(67).  TRP channels are voltage-
independent and are therefore classified as ROCs (though it has been argued that some TRPs 
can be store-operated).  In particular, TRPC6 has been shown to be receptor-operated in 
VSMC, opening in response to Ang II and vasopressin (207; 149).   Activation of a GPCR 
stimulates TRP channels via phospholipase C (PLC)-mediated cleavage of 
phosphatidylinositol bisphosphate (PIP2) to form diacylglycerol (DAG).  DAG then activates 
a signaling pathway independent of protein kinase C (PKC) to stimulate TRP channels to 
allow Ca2+ entry (3). 
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 Besides the channels listed above, it has long been thought that another channel exists 
in the plasma membrane that opens to allow Ca2+entry into the cell after depletion of SR or 
ER stores.  This process was termed "capacitative calcium entry" or "store-operated calcium 
entry" and the putative channels involved were called “Ca2+ release activated Ca2+current 
channels” (CRAC) or store-operated Ca2+ channels (SOC).  Early attempts at the 
identification of SOCs centered around the TRP channels, in particular canonical TRP 
channels (TRPCs) (263; 243; 154; 200; 155; 249; 264).  Fault was seen in most of these 
experiments, however, and TRPC1 is the only TRP channel currently thought to be involved 
in store-operated Ca2+ entry (5; 115).  The main argument against the role of TRP channels 
as SOC is that the large, non-selective currents generated by TRP channels differ from the 
currents generated upon store-depletion (5; 225).  Recently, however, a channel system has 
been identified whose current looks very similar to the traditional CRAC currents.  This 
system consists of two proteins:  Stim1 and Orai1 or Orai2 (169; 205).  Stim1 is thought to 
reside in the membrane of the SR/ER and contain an EF hand domain that senses Ca2+ levels 
inside SR/ER stores. Conformational changes in Stim are thought to cause changes in the 
conformation of Orai whereupon Orai allows Ca2+ to enter the cell through its central pore 
(199).  These new data does not exclude the possibility that TRP channels may also function 
as SOC channels with different currents from the traditional CRAC currents.  Whether or not 
TRP channels use Stim1 as a sensor is currently being debated (199; 5).     
 In the afferent arteriole, Ca2+ entry can be almost obliterated by the L-type voltage-
gated Ca2+ channel antagonist, nifedipine (27).  This is not the case in the efferent arteriole, 
however, and it has been suggested that SOCs are responsible for much of the Ca2+ entry 
(157).  Although less important in Ca2+ entry in the afferent arteriole, SOCs are also present 
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in this vascular segment (58).  Interestingly, Ca2+ entry via L-type channels and SOC is 
enhanced in preglomerular VSMC of the spontaneously hypertensive rat (SHR) (60; 124; 
69).  The roles of Stim1, Orai1 and 2, and TRPC1 store-operated Ca2+ entry in renal VSMC 
remain to be determined. 
 In the SR, ryanodine receptors (RyR) and inositol 1,4,5-trisphosphate receptors 
(IP3R) regulate efflux of Ca2+stores maintained by SERCA.  IP3R are present in the 
membranes of the SR and are activated by IP3.  GPCRs activate PLC leading to cleavage of 
PIP2 into IP3 and DAG.  As mentioned previously, DAG goes on to activate TRP channels in 
the plasma membrane.  IP3 on the other hand, diffuses into the cytoplasm to activate IP3R on 
the SR.  Once activated, a conformational change causes IP3R to release Ca2+ from SR stores 
(218; 182).   
 Type 1 IP3R are expressed in renal afferent arterioles and glomeruli (106) and play 
important roles in vasoconstriction of renal vessels.  IP3 is required for autoregulation in a 
blood perfused juxtamedullary nephron preparation (119).  Ang II-induced Ca2+ transients in 
afferent arterioles(61) and isolated preglomerular VSMC(81), and RBF responses in 
vivo(206) are significantly attenuated during IP3R inhibition.  The actions of 
norepinephrine(208), vasopressin(68), and ghrelin(52) on VSMC [Ca2+]i regulation in the 
renal vasculature are also mediated by IP3. 
 RyR are also present in SR membranes where they function to amplify any small 
increase in [Ca2+]i.  Ca2+ binds directly to the RyR causing a conformational change that 
allows Ca2+ to pass from the SR, through the pore between the four subunits of the RyR, and 
into the cytosol (117).  Recent research indicates that RyR are present in the renal vasculature 
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and participate in renal vascular reactivity to a variety of GPCR agonists (60; 59; 240; 277; 
212).  RyR signaling is discussed at length below. 
 In addition to SR and extracellular stores, a small amount of Ca2+ is maintained in 
other organelles and contributes to overall [Ca2+]i in some cell types.  Late endosomal and 
lysosomal vesicles possess a Ca2+/H+ exchanger that maintains a high concentration of Ca2+ 
in these organelles.  The contribution of these vesicles to renal vasoconstriction has not been 
studied, however both pulmonary and coronary artery VSMC show attenuated Ca2+ signaling 
in the absence of acidified vesicles, indicating participation of lysosomal Ca2+ stores in 
global VSMC Ca2+ responses(274; 135).  It is important to note that the amount of Ca2+ 
inside these vesicles is not large enough to trigger a global Ca2+ response and that RyR 
coupled to lysosomal vesicles most likely amplify small Ca2+ effluxes from acidic vesicles 
(135). 
 Although their function has not been studied specifically in renal microvessel VSMC 
mitochondria also participate in the regulation of [Ca2+]i in some VSMC.  Mitochondria take 
up large quantities of Ca2+ from the cytoplasm.  As a result of this property, mitochondria 
influence [Ca2+]i in two ways:  1) decreases in  [Ca2+]i modulate SOC and 2) positioning of 
mitochondria near Ca2+ channels can alter the influence of that channel on  [Ca2+]i.  
Mitochondria positioned near the SR have also been shown to directly mediate the activity of 
IP3R in the SR(30). 
 Many of the same Ca2+ channels in VSMC are also present in endothelial cells with 
Ca2+ increases activating eNOS and releasing NO to cause vasodilatation(163) as well as 
regulation of PLA2 and production of prostaglandins. Voltage-gated Ca2+ channels (23; 246), 
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store-operated Ca2+ channels(186; 40), IP3R(187; 96), receptor-operated channels(192; 126), 
and RyR(153) are all present in endothelial cells.  Vasodilators such as bradykinin activate 
these channels to enhance NO production (25). 
C.  RYANODINE RECEPTORS--REGULATORS OF [Ca2+]i 
 Half a century ago, the observation was made that ryanodine, an insecticide isolated 
from the South American plant Ryania speciosa could contract skeletal (196) and cardiac 
muscle (109) by excitation-contraction coupling.  At that time it was widely believed that 
Ca2+ release from the SR/ER was due to reversal of SERCA (42).  Studies using 45 Ca2+ then 
led to the discovery that release occurred in the cisternae of the SR/ER, areas in which 
SERCA was absent (174).  The search for the Ca2+ release channel soon focused on 
identification of the target of ryanodine and the RyR was characterized (190).  RyR binding 
assays resulted in the discovery that ryanodine colocalized with the bursts of Ca2+ observed 
in cisternae (75).  The primary function of RyR is Ca2+ mobilization and excitation-
contraction coupling.  In non-skeletal muscle, this largely occurs by amplification of [Ca2+]i 
by Ca2+-induced Ca2+ release (CICR).   
 Early on, scientists determined that skeletal muscle RyR differed structurally and 
functionally from cardiac RyR (116; 171).  Presently, three RyR subtypes have been 
identified and termed RyR1 (the typical skeletal muscle RyR), RyR2 (the primary cardiac 
muscle RyR), and RyR3, a more ubiquitously expressed RyR originally characterized from 
brain tissue (185).  Skeletal muscle RyR are coupled to dihydropyridine receptors in the 
skeletal muscle plasma membrane so that opening of these channels directly triggers release 
of Ca2+ from the SR by conformational coupling(270).  Ca2+ entry is not a prerequisite for 
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RyR opening in skeletal muscle.  Rather, a conformational change of the dihydropyridine 
receptor leads to RyR opening (16).  Non-skeletal RyR do not physically interact with 
voltage-gated Ca2+ channels, but rather amplify Ca2+ by CICR secondary to Ca2+ entry.  The 
magnitude of Ca2+ release elicited by RyRs may vary according to subtype.  Whereas RyR1 
and RyR2 are thought to primarily mediate cellular-wide global Ca2+ responses, stimulation 
of RyR3 releases only small amounts of Ca2+ from the SR/ER in highly localized regions 
(251; 195).  These small Ca2+ “sparks” may exist in microdomains near Ca2+-activated K+ 
channels to produce membrane hyperpolarization (156; 137). 
 Gating of RyRs and/or sensitivity to Ca2+ can be altered by a variety of factors 
including protein binding, ion binding, oxidation, nitrosylation, and phosphorylation.  
Calmodulin binds to RyR in both Ca2+ bound and unbound states.  In skeletal muscle, Ca2+ 
bound calmodulin impairs RyR gating, whereas Ca2+ free calmodulin enhances activity (80).  
In cardiac muscle, calmodulin inhibits RyR opening independent of whether it is bound to 
Ca2+ (168) and decreases RyR2 sensitivity to Ca2+(15).  Calmodulin also alters RyR 
sensitivity by activating calcium/calmodulin-dependent protein kinase II (CaMII), leading to 
phosphorylation and activation of RyR(259; 99).  RyR in cardiac muscle can also be 
phosphorylated by protein kinase A (PKA).  PKA is anchored to RyRs by the A kinase 
anchoring protein mAKAP (15).  The effect of serine phosphorylation by PKA is 
controversial.  Some labs suggest that phosphorylation impairs binding of inhibitory FK506 
binding proteins (FKBP) leading to activation(164; 165).  These results have been contested, 
however (226; 262).  In renal VSMC, activation of PKA by prostaglandin PGI2 may lead to 
vasodilation by inhibiting IP3-mediated Ca2+ release (198). 
14 
 
 Several other proteins have been shown to regulate RyR activity.  Most notably, the 
FKBP, known for their affinity for the immunosuppressant FK506 (tacrolimus) are potent 
inhibitors of RyR.  FKBP stabilize the RyR tetramer and decrease sensitivity to Ca2+(15).  
RyR1 and RyR3 specifically associate with FKBP12.  RyR2 can associate with both FKBP12 
and FKBP12.6, with much higher affinity for FKBP12.6 (15).  Sorcin is also inhibitory and 
may help turn off RyR responses since it binds to RyRs only in the presence of high [Ca2+]i 
(15).  Calsequestrin, a SR/ER Ca2+ binding protein, may inhibit RyR by forming a complex 
with junction and triadin and binding to RyR when [Ca2+]SR/ER is low(97).  The adapter 
protein homer inhibits RyR2 and activates RyR(15). 
 Ca2+ can activate RyR from both the cytosol and the SR/ER lumen.  Cytosolic Ca2+ 
can inhibit RyR1 at high concentrations (1 mM), and RyR2 at even higher concentrations (10 
mM) (144).  In addition to Ca2+, 2 mM Mg2+ can also bind RyR1 and 2 to competitively 
inhibit RyR responses to Ca2+.  In the presence of physiological ATP (5 mM), free [Mg2+] is 
low (0.5-1 mM) since most Mg2+ is bound by ATP.  In this way, ATP enhances RyR activity 
through decreasing free Mg2+.  Under certain physiological conditions such as ischemia, 
however, ATP levels decrease and Mg2+ levels increase, causing Mg2+-induced inactivation 
of RyRs(15).  RyR3s are not inhibited by Ca2+ or Mg2+ (144). 
 All 3 RyR exist in VSMC (107; 181) and RyR have been implicated in VSMC 
responses to constrictor responses to Ang  II(61), norepinephrine(173), acetylcholine(87), 
and endothelin-1(62; 135) and dilatory responses to agmatine, bradykinin, and NO(276).  
D.  IDENTIFICATION AND CHARACTERIZATION OF ADP RIBOSYL CYCLASE 
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 IP3 was identified in the early 1980s as a second messenger responsible for Ca2+ 
mobilization (230).  Subsequent studies showed incidences where Ca2+ mobilization in 
several cell types such as airway epithelium, pancreatic beta cells, and sea urchin oocytes can 
occur in the presence of little or no IP3 production (167; 233).  Cyclic ADP ribose (cADPR) 
was one of several compounds identified in the search for Ca2+ mobilizing metabolites along 
with sphingosine derivatives, cyclic IP3, arachadonic acid, and inositol tetrakisphosphate 
(256).  While there were  little data ever produced indicating the importance of the other 
identified compounds in vivo, cADPR is  equally potent at mobilizing Ca2+ as IP3 (45)  and is 
present in a variety of mammalian tissues including brain, heart, and liver (247).  
Furthermore, an endogenous producer of cADPR, ADP ribosyl cyclase (ADPR cyclase) was 
isolated from the ovotestes of the sea hare Aplysia californica (145) and subsequently found 
to share homology with two mammalian enzymes:  CD38 and CD157 (231; 112).  It is 
possible that other mammalian isoforms exist including a form specific to aortic VSMC (49) 
and one unique to mesangial cells(178; 134).   
 Further characterization revealed that ADPR cyclases catalyze a reaction 
transforming NAD+ to cADPR and nicotinamide(93).  In dimeric form, ADPR cyclases 
residing in the plasma membrane produce cADPR, functioning optimally at a pH of 6.7.  In 
addition plasma membrane cyclases act as ADPR hydrolases, converting cADPR to ADPR.  
Dimeric ADPR may enhance the Ca2+ mobilizing actions of cADPR(46).  Studies using 
erythrocyte ghosts showed that the catalytic activity of ADPR cyclases occurs primarily in 
the extracellular domain (147).  As a result of a large pore formed between monomers in the 
dimeric form, it was hypothesized that cADPR is formed extracellularly and transported 
through the pore into the cell where it acts to mobilize Ca2+ (78).   3T3 fibroblasts lacking 
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ADPR cyclase also transport cADPR, however, so other nucleoside transporters responsible 
for importing extracellularly-formed cADPR must exist (78).  One conundrum remained, 
however.  Extracellular concentrations of NAD+ are low except during cases of tissue 
necrosis, so how does the extracellular enzymatic portion of ADPR cyclase access regulated 
levels of its substrate?  To answer this question, experiments were performed in which 
connexin 43 hemichannels were shown to colocalize with ADPR cyclase in the plasma 
membrane and transport NAD+ (78).  It is currently thought that the hemichannels provide a 
high enough local concentration of NAD+ near the extracellular domain of the cyclase to 
drive the forward reaction, producing cADPR.  It has also been proposed that 
uncharacterized channels exist that link adjacent cells to transport cADPR from one cell to 
another.  This has been demonstrated in tracheal smooth muscle strips whose [Ca2+]i 
increases in response to cADPR production by neighboring mucosal cells.  
 It is clear that cyclase dimerization is required for cADPR production.  The remaining 
question is what signal produces dimerization.  Like many molecules, dimers of ADPR 
cyclase form via disulphide bonding, a likely consequence of oxidation of thiol groups by 
superoxide.  Oxidative stress enhances cADPR production by ADPR cyclases of bovine 
coronary artery VSMC (271).  In isolated afferent arterioles, Ang II increases superoxide 
production and Ca2+ responses are inhibited by the superoxide dismutase mimetic tempol 
(64).  In the same study, Ca2+ responses to Ang II were also shown to be attenuated in the 
presence of the NADPH oxidase inhibitor apocynin (64).  The already attenuated responses 
show no further inhibition by subsequent addition of the ADPR cyclase inhibitor 
nicotinamide, suggesting a common signaling pathway.  Collectively, these experiments 
indicate that ADPR cyclase is likely activated by NADPH oxidase-induced production of 
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superoxide in the plasma membrane.  Recent research indicates that ADPR cyclase may also 
activate NADPH oxidase in the SR membrane of bovine coronary arterial myocytes(275).  
Application of a cell permeable indicator of reactive oxygen species showed local generation 
of superoxide near the SR membrane that was blocked by inhibitors of NADPH oxidase, 
ADPR cyclase, or RyR.  Since redox status may alter RyR activity, it was suggested that 
superoxide from SR NADPH oxidase may directly increase the probability of opening of 
RyR.  This hypothesis remains to be tested, however. 
 It was obvious from early studies that IP3 and cADPR signaling overlapped based on 
the characteristics of Ca2+ release induced by cADPR and IP3 in sea urchin egg homogenates 
(45).  For this reason, it was first thought that cADPR may activate IP3Rs in the ER 
membrane.  This was proven not to be the case as inhibitors of IP3R had no effect on 
cADPR-induced Ca2+ release (45) and since IP3 did not competitively displace radiolabelled 
cADPR (146).  The mechanism of cADPR-induced Ca2+ mobilization was discovered to 
occur via binding to RyR in the ER membrane (83).  When ryanodine was given at an 
inhibitory dose of 100µM, cADPR-induced Ca2+ mobilization from rat brain microsomes 
was attenuated (254).  Other studies showed that cADPR increases the frequency of cardiac 
RyR channel opening (170).  Photoaffinity labeling revealed that cADPR binds to two 
proteins, both much smaller than RyR, indicating that cADPR most likely did not directly 
bind to RyR (248).   
It was soon determined that a family of inhibitory FK506 binding proteins including 
FKBP12 and FKBP12.6 bind to  RyR to prevent Ca2+ activation(242).  Pharmacologically, 
FK506 removes FKBP from RyR, increasing open probability of RyR (239).  Experiments in 
pancreatic cell microsomes show that cADPR removes FKBP12.6 from RyR and that 
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microsomes lacking FKBP12.6 show no Ca2+ release in response to cADPR.  These results 
suggest that cADPR activates RyR by removing inhibitory FKBP (184).  Further evidence 
for this hypothesis comes from experiments on reconstituted RyR from bovine aortic VSMC.  
An antibody against FKBP12 prevents cADPR-induced increases in the probability of 
opening of RyRs (239).  Tracheal myocytes lacking FKBP12.6 do not respond to cADPR 
(250). 
 While knowledge of the specific intracellular actions of cADPR was expanding, a key 
discovery solidified the significance of ADPR cyclase as an important regulator of [Ca2+]i.  
In addition to IP3 and NAD+, NADP could also cause Ca2+ release from sea urchin 
microsomes (41).  This Ca2+ release was insensitive to the IP3R inhibitor heparin and the 
cADPR competitive antagonist 8-amino-cADPR and occurs by production of nicotinic acid 
adenine dinucleotide phosphate (NAADP) (148).  Furthermore, thionicotinamide-NADP, an 
analogue of NADP which does not inhibit IP3- or cADPR-induced Ca2+ release, inhibited the 
actions of NAADP injected into sea urchin eggs (35).  Endogenous NAADP releases Ca2+ 
from internal stores of a variety of mammalian tissues as well (34).   
The search for the mechanism by which NAADP is generated in intact cells was soon 
underway.  ADPR cyclase isolated from Aplysia californica and human CD38 could 
synthesize NAADP from NADP in an in vitro setting at a pH of 4.0(1).  This requirement for 
a low pH was a welcome surprise since both Aplysia ADPR cyclase and CD38 were known 
to internalize into endocytic vesicles (1; 221; 47).  After it was determined that ADPR 
cyclases produced NAADP, the question remained as to how NAADP was degraded.  An 
efficient second messenger must be degraded to ensure sensitivity of the system.  Recent 
experiments show that, like cADPR, NAADP can be converted to ADP-ribose 2'-phosphate 
19 
 
by CD38 (94), thus reversing the actions of NAADP production.  Unlike synthesis of 
NAADP, which only occurs at low pH, breakdown of NAADP can occur at physiological or 
low pH. 
NAADP induces colocalization of lysosomal vesicles with RyR (135; 136).  This idea 
spurred the “trigger zone” hypothesis proposed by Kinnear et al.  These investigators thought 
that NAADP receptors inside of lysosomal vesicles allowed small amounts of Ca2+ to exit the 
vesicle upon production of NAADP by lysosomal ADPR cyclase.  It was later shown that 
NAADP binds to TRP-ML1 channels in lysosomal membranes to cause this Ca2+ release (2; 
14).  This small amount of Ca2+ activates nearby RyR on the SR/ ER to amplify the signal 
and cause global Ca2+ increases.  Another recent advance in thinking about NAADP 
signaling is based on the observation that NAADP (isolated from sea urchin eggs) requires a 
phospholipid environment to potentiate binding to its receptor (37).  NAADP might also be 
produced by ADPR cyclases in lipid rafts or calveole in addition to production in lysosomal 
vesicles.  Cell membranes of pulmonary VSMC fractionated based on cholesterol content 
reveal that regions enriched in cholesterol (lipid rafts/calveolae) contain high levels of CD38.  
Furthermore, cholesterol depletion attenuates Ca2+ responses to endothelin ETB receptor 
stimulation and ETB -mediated enhancement of ADPR cyclase activity was abolished in the 
absence of calveolae.   More research is needed to explore this exciting new aspect of 
NAADP signaling. 
E.  EVIDENCE SUGGESTING A ROLE FOR ADPR CYCLASE IN NON-RENAL 
VASCULAR SMOOTH MUSCLE 
 Due to the virtually ubiquitous role of ADPR cyclase in Ca2+ signaling and the 
importance of Ca2+ signaling in regulation of vascular tone, it is not surprising that the 
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hypothesis appeared shortly after the discovery of cADPR and NAADP that these second 
messengers are important in hemodynamics.  Indeed, eight years after the initial 
characterization of cADPR from sea urchin eggs, the first study was published examining the 
effects of this second messenger on Ca2+ mobilization from the SR of coronary arterial 
myocytes (132).  In this study, porcine VSMC were permeabilized and injected with cADPR.  
cADPR increased [Ca2+]i in these cells, an effect that was not blocked by the IP3R inhibitor 
heparin.  Depletion of SR Ca2+ stores resulted in no effect of cADPR.  Not only is ADPR 
cyclase present in VSMC, but activity is at least 20 times higher than that seen in HL-60 
cells, an immune cell type containing the ADPR cyclase/antigen CD38(50).  cADPR was 
subsequently shown to increase Ca2+ in aortic VSMC microsomes(269).  Inhibition of ADPR 
cyclase produced relaxation of pre-contracted coronary artery rings, indicating a role for 
ADPR cyclase in the maintenance of vascular tone (88).  Although prior to the work 
presented herein, therewas no current evidence implicating ADPR cyclase in regulation of 
vascular tone in an animal in vivo, pulmonary arteries had been shown to be prevented from 
constricting under hypoxic conditions in rat lung in situ (53). 
 Characterization of VSMC ADPR cyclase revealed the enzyme to be similar to 
previously characterized ADPR cyclases.  A selective antagonist of cADPR, 8Br-cADPR 
attenuated KCl-induced Ca2+ and contractile responses in isolated small coronary arteries 
(273), indicating involvement of cADPR in CICR.  Like other cell types, cADPR increases 
the open probability of RyRs reconstituted from coronary artery VSMC (151).  cADPR in 
VSMC also likely works by removal of FKBP12.6 from RyRs since FKBP12.6 and not 
FKBP12 is expressed in coronary arterial VSMC and since both FK506 and a nonselective 
FKBP antibody attenuate the increase in open probability of reconstituted RyRs observed 
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after treatment with cADPR(239).  The similarities of ADPR cyclase signaling between cell 
types is not surprising considering the ubiquitous nature of CD38, an ADPR cyclase family 
member expressed in VSMC(50; 173).  Another ADPR cyclase family member may exist 
with properties different from CD38.  Unlike CD38 from HL-60 cells, aortic ADPR cyclase 
is inhibited by Zn2+ and Cu2+ and activated by retinoic acid and 3,5,3'-triiodothyronine, a 
property different from HL-60 cell CD38(50).  Furthermore, unlike ADPR cyclase in 
endothelial cells (276) and sea urchin egg homogenates(255), VSMC ADPR cyclase is 
inhibited by NO(266), suggesting cell type specific properties of ADPR cyclases. 
 Although the data are sparse, ADPR cyclase is likely also present in endothelial cells.  
ADPR cyclase activity is present in coronary artery endothelial cells under resting 
conditions.  This activity is increased by the vasodilator bradykinin and 8Br-cADPR impairs 
bradykinin-induced Ca2+ transients in intact coronary artery endothelium (276) indicating a 
possible role for ADPR cyclase in bradykinin-mediated dilation secondary to Ca2+ activation 
of eNOS.  
 Of physiological relevance, ADPR cyclase is likely a downstream target for a variety 
of G protein coupled receptors (GPCRs) important in vascular health and disease.   Small 
mesenteric arteriolar contractile responses (90) and shark anterior mesenteric arterial Ca2+ 
responses (62) to endothelin-1(ET-1) are attenuated in during ADPR cyclase and cADPR 
inhibiton.  Contractile responses to norepinephrine are smaller in aortas of CD38-/- mice than 
in wild type control animals(173) and coronary artery SMC responses to acetylcholine are 
attenuated by inhibitors of ADPR cyclase and cADPR(87), further proof of the important role 
of ADPR cyclase in agonist-induced responses in VSMC.  NAADP may be particularly 
important in VSMC responses to endothelin-1.  Coronary arterial SMCs produce NAADP in 
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response to ET-1 (274) and both pulmonary (135) and coronary (274) arterial VSMC Ca2+ 
responses are significantly blunted by disrupters of NAADP signaling.  
F.  EVIDENCE SUGGESTING A ROLE FOR ADPR CYCLASE IN THE KIDNEY 
 CD38 and CD157 are both expressed at high levels in kidney tissue (122; 234).  In 
addition, there is evidence suggesting that the kidney may express an alternative form of 
ADPR cyclase since the inhibitor 4,4-dihydroxyazobenzene is reported to inhibit ADPR 
cyclase in kidney but not human CD38 or ADPR cyclase from other tissues(178).  The 
kidney is an extremely heterogeneous tissue, however, where many specialized cell types 
work together to achieve the overall goal of capillary fluid exchange and epithelial transport.  
In vitro studies indicate that ADPR cyclase likely mediates key functions of many kidney 
tissue types.  The concerted effort of VSMCs and endothelial cells in small arterioles, 
including the afferent arterioles controls vascular resistance and the volume of blood passing 
through the glomerulus and ultrafiltrate into the tubules.  ADPR cyclase activity is present in 
VSMC of small renal arterioles where it mediates increases in [Ca2+]i as shown by cADPR 
injection into permeabilized single renal VSMC (150), and the cADPR inhibitor 8Br-cADPR 
attenuates responses to CaCl2 in small renal VSMC, indicating participation of cADPR in 
CICR.  The strength of this hypothesis is solidified by findings that Ca2+ increases by KCl-
induced hyperpolarization in isolated renal afferent arterioles are attenuated in the presence 
of 8Br-cADPR (66).   
 Much recent work has been done indicating that isolated renal afferent arterioles rely 
heavily on ADPR cyclase and cADPR to mediate signaling pathways downstream of GPCR.  
Ang II-induced Ca2+ responses in afferent arterioles were significantly attenuated in the 
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presence of ADPR cyclase inhibitors nicotinamide and Zn2+ or 8Br-cADPR (61).  Addition 
of superoxide inhibitors did not enhance this effect of ADPR cyclase inhibitors, but did 
attenuate Ang II-induced Ca2+ transients on their own, indicating a dependence of ADPR 
cyclase signaling responses to Ang II on superoxide production(64).  ETA receptor signaling 
is also inhibited by nicotinamide and 8Br-cADPR more than signaling mediated by ETB 
receptors, suggesting heterogeneity amongst GPCR signaling pathways in the renal 
vasculature (65). 
 Although very little work has been done to confirm the fact, endothelial cells of 
preglomerular resistance arterioles may also possess ADPR cyclase signaling pathways 
downstream of vasodilators.  One study showed that agmatine, a vasodilator that works by 
increasing NO production in endothelial cells produces its effects by activation of ADPR 
cyclase.  Single nephron GFR is increased by agmatine, indicative of vasodilatation of 
preglomerular resistance arterioles, an effect attenuated in the presence of 8Br-cADPR (212). 
 Glomerular mesangial cells have very high ADPR cyclase activity (36) when 
compared to whole kidney homogenates.  The expression and activity of CD38 in these cells 
is regulated by TNF-α, indicating a likely immune function (268).  cADPR may function to 
regulate mesangial cell proliferation and protein synthesis via alterations in [Ca2+]i (134).  
NAADP also elicits Ca2+ release from isolated mesangial cell microsomes, but the effect of 
this release is unknown (267).  Glomeruli also have very high levels of ADPR cyclase 
activity (36), though little is known about the precise function of ADPR cyclase in glomeruli. 
 Juxtaglomerular cells at the end of the afferent arteriole produce renin to regulate 
levels of local and circulating Ang II for long-term regulation of GFR and tubular salt 
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reabsorption as well as aldosterone production.  Cultured As4.1 juxtglomerular cells produce 
cADPR for the regulation of [Ca2+]i (265).  Increased [Ca2+]i commonly inhibits renin 
synthesis and release (216) .  Further study is required to determine the physiological 
importance of cADPR or ADPR cyclase in renin release.  
G. STATEMENT OF PURPOSE 
 I have tested the hypothesis that the ADPR cyclase signaling cascade participates 
importantly to the regulation of renal hemodynamics.  To this end, I have used a combination 
of [Ca2+]i measurements and molecular biological analysis of ADPR cyclase mRNA levels in 
isolated preglomerular resistance arterioles and in vivo RBF and MAP measurements in 
anesthetized rats and mice.  These studies provide the first evidence indicating renal vascular 
expression of ADPR cyclases as well as a physiological role for the enzyme and its 
downstream targets in the regulation of renal afferent arteriolar [Ca2+]i, baseline RBF 
regulation, and integrated RBF responses to GPCR agonist-induced renal vasoconstriction.  
Characterization of the physiological effects of this pathway will further our knowledge of 
the regulation of renal hemodynamics in health and disease. 
  
  
CHAPTER II 
 
ADP-ribosyl cyclase and ryanodine receptor activity contribute to basal renal vasomotor tone 
and agonist-induced renal vasoconstriction in vivo  
 
 
 
 
 
 
 
 
 
 
 
Reprinted with permission from American Journal of Physiology Renal Physiology 293:  
F1107-1114.  Copyright © 2009 by the American Physiological Society.  All rights of 
reproduction of any form reserved. 
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A. ABSTRACT 
 An important role for the enzyme ADP-ribosylcyclase (ADPR cyclase) and its 
downstream targets, the ryanodine receptors (RyR), is emerging for a variety of vascular 
systems.  We hypothesized that the ADPR cyclase/RyR pathway contributes to regulation of 
renal vasomotor tone in vivo.  To test this, we continuously measured renal blood flow 
(RBF) in anesthetized Sprague-Dawley rats.  Infusion of the ADPR cyclase inhibitor 
nicotinamide intrarenally at low doses inhibits angiotensin II (Ang II)- and norepinephrine 
(NE)-induced vasoconstriction by 72% and 67% (P<0.001).  RBF studies in rats were 
extended to mice lacking the predominant form of ADPR cyclase (CD38).  Acute renal 
vasoconstrictor responses to Ang II and NE are impaired by 59% and 52%, respectively in 
anesthetized CD38-/- mice compared to wild type controls (P<0.05). Intrarenal injection of 
the RyR activator FK506 decreases RBF by 22% (P<0.03).  Furthermore, RyR inhibition 
with ruthenium red attenuates Ang II and NE responses by 50% and 59%, respectively 
(P≤0.01).  Given at higher doses, nicotinamide increases basal RBF by 22% (P<0.001).  Non-
receptor-mediated renal vasoconstriction by L-type voltage-gated Ca2+ channels is also 
dependent on ADPR cyclase and RyRs. Nicotinamide and ruthenium red inhibit constriction 
by the L-type channel agonist Bay-K8644 by 59% (P<0.02) and 63% (P<0.001).  We 
conclude that: 1) ADPR cyclase activity contributes to regulation of renal vasomotor tone 
under resting conditions, 2) renal vasoconstriction induced by G-protein coupled receptor 
agonists Ang II and NE is mediated in part by ADPR cyclase and RyRs, and 3) ADPR 
cyclase and RyRs participate in L-type channel-mediated renal vasoconstriction in vivo. 
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B.  INTRODUCTION 
 Regulation of renal hemodynamics is essential for the maintenance of fluid and 
electrolyte balance and arterial blood pressure.  Recent rises in morbidity and mortality rates 
associated with obesity and hypertension have made apparent the urgency of understanding 
the molecular mechanisms of blood pressure regulation, resulting in discovery of complex, 
integrated Ca2+ signaling pathways for regulation of renal vascular resistance (RVR) (6; 
210).  Stimulation of these pathways leads to increases in cytosolic Ca2+ concentration 
([Ca2+]i) via activation of plasma membrane Ca2+ channels as well as Ca2+ release channels in 
the sarcoplasmic reticulum (SR).  The latter include inositol trisphosphate receptors (IP3Rs) 
and ryanodine receptors (RyRs).   The wide variety of mechanisms involved in [Ca2+]i 
regulation make it possible for vascular smooth muscle cells (VSMCs) to generate 
individualized responses to different vasoconstrictor stimuli.  For example, it has been 
suggested that greater than 50% of angiotensin II (Ang II)-induced changes in [Ca2+]i in 
afferent arterioles occurs by Ca2+ entry, whereas the actions of norepinephrine (NE) are more 
dependent on Ca2+ mobilization from internal stores (210).  
 The role of IP3Rs in agonist-induced regulation of vascular resistance has been 
extensively studied (73; 119; 206; 208).  Considerably less is known about the role of RyRs 
in agonist-induced constriction in renal and other vascular beds (21; 51).  One means of RyR 
activation involves the enzyme ADP ribosyl cyclase (ADPR cyclase) and generation of the 
second messengers cyclic ADP ribose (cADPR) and nicotinic acid ADP (NAADP) (61; 272).  
Evidence indicates ADPR cyclase is important in Ca2+ signaling in the renal vasculature.  
Cyclase activity is high in lysates from VSMCs in renal microvessels and glomeruli(36; 150) 
and cADPR applied extracellularly to isolated permeabilized VSMCs from rat renal artery 
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increases [Ca2+]i (150).  Furthermore, cADPR contracts isolated rat interlobular arteries 
(150), and inhibition of ADPR cyclase, cADPR, or RyRs attenuates Ca2+ responses to Ang II 
or endothelin-1 (ET-1) in isolated rat afferent arterioles (61; 65).  These in vitro studies 
demonstrate a potential physiological role for the enzyme in the renal microcirculation. 
 Whereas in vitro stimulation of ADPR cyclase activity in VSMCs leads to activation 
of pathways implicated in vasoconstriction, the actions of this enzyme in endothelial cells are 
predicted to cause vasodilatation.  Inhibition of ADPR cyclase, cADPR, or RyRs is reported 
to prevent production of nitric oxide (NO), a potent vasodilator, in response to bradykinin or 
the Ca2+ ionophore A-23187 in bovine coronary artery endothelium (272).  In some cases, 
ADPR cyclase in VSMCs may lead to dilation rather than constriction.  This is suggested by 
the fact that inhibition of cADPR in isolated rat renal arteries attenuates relaxation produced 
by urocortin (211). 
 The importance of the ADPR cyclase/RyR signaling pathway has not been 
determined in any vascular network in vivo.  Although experiments in isolated cells and 
vessels provide useful information regarding the nature of ADPR cyclase, the seemingly 
opposite results of ADPR cyclase activation in VSMCs and endothelial cells in vitro do not 
integrate possible interactions between endothelial cells and VSMCs that occur in vivo. To 
address this deficiency, we tested the hypothesis that the ADPR cyclase pathway contributes 
to both basal renal vascular tone and vasoconstriction produced acutely by Ang II, and 
norepinephrine (NE), and the L type voltage-gated Ca2+ channel agonist, Bay-K8644.  The 
effects of pharmacological inhibitors of ADPR cyclase and its downstream effectors, RyRs, 
were determined in acute RBF studies conducted on anesthetized rats.  The effects of genetic 
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deletion of ADPR cyclase were determined in acute RBF studies comparing mice lacking the 
predominant form of ADPR cyclase (215), CD38 (CD38-/-) with wild type animals. 
C.  MATERIALS AND METHODS  
 Sprague-Dawley rats were obtained from our local breeding facility.  CD38-/- mice 
on a C57 black 6 background were obtained as breeding pairs from Dr. Fran Lund (Trudeau 
Institute, (188)) and bred locally.  Wild type mice of a similar background were obtained 
from Jackson Labs as breeder pairs.  All animals were cared for and used for research in 
accordance with institutional guidelines. Animals were anesthetized using sodium 
pentobarbital (Nembutal, 50-60 mg/kg body wt ip for rats, 80-90 mg/kg body wt ip for mice, 
Abbott, Chicago, IL).   
 The surgical preparation for acute RBF studies in rats was performed as is standard 
for our laboratory (129).  Briefly, the right femoral artery was catheterized for continuous 
measurement of MAP.  The right femoral vein was catheterized for infusion of bovine serum 
albumin (4.75% at 50 µl/min for a length of time equal to body wt/4, then reduced to 
10µl/min for the remainder of the experiment) and administration of subsequent doses of 
pentobarbital as needed.  A tracheotomy was performed and a curved catheter was inserted 
into the aorta and positioned at the opening of the left renal artery for direct intrarenal 
infusion of pharmacological agents.  RBF was measured in the left renal artery by a flow 
probe (model 1RB, Transonic, Ithaca, NY). 
 The surgical preparation for RBF studies in mice was previously established in our 
laboratory (19) and modified for the purposes of this study.  Briefly, a pulled PE100 catheter 
was inserted into the right femoral artery and attached to a pressure transducer (Statham P23 
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DB) for measurement of MAP.  Two pulled PE10 catheters were inserted into the femoral 
vein for bolus injections of Ang II and NE and continuous infusion of 2.4% bovine serum 
albumin (10 µl/min) throughout the experiment.  A tracheotomy was performed using a 
PE100 catheter.  A flow probe (Transonic system TS420, Ithaca, NY; 0.5-V probe) was 
placed around the left renal artery for measurement of RBF.  Animals were allowed to 
stabilize for 1 hr prior to the start of an experiment.  Hematocrit, urine flow, kidney wt, and 
body wt were measured to ensure consistency of animal conditions. 
 Bolus Injections- For rats, bolus injections (10 µl) were given intrarenally in the 
manner standard in our laboratory (129).  The following concentrations were used:  Ang II 
(0.38 µM = 4 ng), NE (9.75 µM = 20 ng), FK506 (31 mM = 250 µg), Bay-K8644 (0.70 mM 
= 2.5 µg).  The same doses of Ang II and NE were used for 10 µl venous injection in mice. 
 Pharmacological Inhibitors- We used nicotinamide to inhibit ADPR cyclase (24; 88; 
152; 172).  Nicotinamide is a byproduct of the ADPR cyclase reaction(145), and shifts the 
reaction to produce NAD+ rather than cADPR or NAADP.  Nicotinamide may also inhibit 
Poly (ADP-ribose) polymerase-1 (PARP-1) (179; 260).  PARP-1 is found in both endothelial 
cells (232) and VSMCs (91) and is activated under situations of extreme stress (8).  Since the 
animals used in our study were closely monitored for stable hemodynamic conditions, 
activation of PARP-1 is unlikely. 
 Ruthenium red was used to inhibit RyRs.  The effects of ruthenium red on RyRs are 
well documented (39; 161).  Ruthenium red may also inhibit Ca2+-activated K+ channels 
(BKCa) (261).  Although these channels have been shown to be present in renal microvessels 
(57), BKCa channel inhibition would result in vessel contraction and our studies show 
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ruthenium red inhibits agonist-induced contraction, arguing that the predominant effect of 
ruthenium red is on RyRs. 
Nicotinamide or ruthenium red was infused into the renal artery at 140 µl/min for 3 
min before vasoconstrictor injection and continued for an additional 2 min.  Multiple doses 
of these agonists were tested in the same animal.  Concentrations of ruthenium red and 
nicotinamide were based upon in vitro published concentrations (61; 63) and calculated as 
estimated final renal arterial concentration.  Concentrations that altered MAP or RBF were 
not used to inhibit vasoconstrictive agents.  The target plasma concentrations of nicotinamide 
and ruthenium red are  3 mM (6 mg/kg/min) and 5 µM (126 µg/kg/min) in the renal artery, 
respectively. 
 Inhibitors were given at the highest dose that did not significantly alter basal RBF or 
MAP.  The estimated plasma concentration of nicotinamide (3 mM) is higher than the IC50 of 
nicotinamide on cyclase activities of sea urchin egg homogenates (1.5 mM) and ADPR 
cyclase isolated from Aplysia californica (0.04 mM) (219).  Concentrations from 3-5 mM 
have also been shown to inhibit Ca2+ responses to β-NAD, the substrate for ADPR cyclase in 
sea urchin egg homogenates after 2 min (219) and inhibit Ca2+ responses to Ang II in isolated 
afferent arterioles shortly after application (61).  Infusion of nicotinamide at 6 mg/kg/min is 
therefore likely sufficient to inhibit ADPR cyclase activity.  Similarly, the estimated plasma 
concentration of ruthenium red (5 µM) is much higher than the IC50 published for ruthenium 
red on isolated RyR from rabbit skeletal muscle (117). 
Inhibition of Basal Vascular Tone- To evaluate activity of ADPR cyclase under 
resting conditions, a high dose of nicotinamide (12 mg/kg/min) was infused into the renal 
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artery for 20 min at 140 µl/min.  The animal was then allowed to rest for 20 min, during 
which time RBF returned to normal. Multiple doses were given to the same animal.  
Concentrations after which RBF did not return to normal or MAP changed were not used. 
Pharmacological Agents- Nicotinamide, ruthenium red, Bay-K8644, and Ang II were 
obtained from Sigma (St Louis, MO), FK506 was from Cayman Chemical (Ann Arbor, MI), 
and NE was from Abbott Labs (Chicago, IL).  NE, Ang II, ruthenium red, and nicotinamide 
were dissolved in 0.9% NaCl.  Bay-K8644 and FK506 were dissolved in 10% DMSO and 
0.9% NaCl. 
Data Analysis- Data were collected using Labtech Notebook software and graphs 
were created using Sigma Plot software.  Statistics were performed by one way ANOVA test 
using Sigma Stat software. 
D.  RESULTS 
 Results are reported on 36 Sprague-Dawley rats whose age averaged 7.6 ± 0.1 weeks.  
Under basal conditions, mean MAP, RBF, hematocrit, and urine flow were 112 ± 3 mmHg, 
4.47 ± 0.23 ml/min/g kidney wt, 43 ± 1%, and 32 ± 2 µl/min, respectively.  Due to the 
reversible nature of Bay-K8644, FK506, Ang II, and NE, bolus injections of multiple agents 
could be given within the same animal.  Only one inhibitor was used in an animal; each rat 
received either nicotinamide or ruthenium red. 
 ADPR cyclase activity mediates vasoconstriction produced by Ang II and NE.  To 
determine the physiological importance of ADPR cyclase activity in agonist-induced renal 
vasoconstriction, we assessed the effect of the ADPR cyclase inhibitor nicotinamide on the 
acute renal response to Ang II.  Ang II injected into the renal artery decre
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3% in the control period (Fig. 2.1A and B).  Intrarenal infusion of nicotinamide (≤6 
mg/kg/min) did not significantly alter baseline MAP or RBF, but attenuated RBF responses 
to Ang II to a 7 ± 2% decrease in RBF (P<0.001).  This effect of nicotinamide was rapidly 
reversible; the RBF response to Ang II was completely restored after 10 min (Fig. 2.1B).  
These data demonstrate that ADPR cyclase activity strongly influences Ang II-mediated 
renal vasoconstriction in vivo. 
 We also tested nicotinamide's ability to inhibit NE-induced renal vasoconstriction.  
NE injected into the renal artery produced an average 24 ± 3% decrease in RBF (Fig. 2.2A 
and B).  Short-term nicotinamide infusion inhibited the effect of NE by ~70%, as NE 
decreased RBF to 8 ± 1% of normal (P<0.001).  These data indicate that ADPR cyclase 
activation contributes to a significant percentage of NE-induced renal vasoconstriction.  In 
the recovery period, the response to NE was greater than control. 
 ADPR cyclase activity contributes to renal vasoconstriction induced by L-type 
voltage-gated Ca2+ channels.  Since nicotinamide similarly inhibited Ang II- and NE-
induced contraction despite reported differences in the degree of Ca2+ mobilization (210), we 
tested whether basal activity of ADPR cyclase contributes to vasoconstriction produced 
independently of GPCRs.  For this purpose, we evaluated renal vasoconstriction triggered by 
directly activating L-type voltage-gated Ca2+ channels using the agonist Bay-K8644. 
Intrarenal BayK-8644 injection produced a 78 ± 7% decrease in RBF (Fig. 2.3A and B).  
This response was inhibited by 59% with nicotinamide (P=0.01), attenuating constriction to 
33 ± 12% of baseline RBF.  Again, the effects of nicotinamide were reversible; the response 
to Bay-K8644 returned to normal after 10 min.  These data establish a physiological role of 
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basal ADPR cyclase activity in constriction induced by Ca2+ entry via voltage-gated Ca2+ 
channels.  
Basal renal vasomotor tone involves ADPR cyclase activity   Doses of nicotinamide 
used to inhibit Ang II, NE, and Bay-K8644 did not significantly alter RBF or MAP when 
infused into the renal artery for 3 min (Fig. 2.4A) prior to vasoconstrictor injection.  To 
determine the contribution of ADPR cyclase activity to basal renal vascular tone in vivo, we 
infused nicotinamide at a higher dose (12 mg/kg/min for 20 min).  At this dose, localized 
relaxation of the renal vasculature was observed (Fig. 2.4B).  RBF increased by 22 ± 4% 
(P<0.001) without changing MAP.  Doses higher than 12 mg/kg/min reduced MAP, 
indicating systemic effects, and were therefore not used.  Our results demonstrate that 
nicotinamide inhibits the tonic renal actions of endogenous stimuli signaling through ADPR 
cyclase to maintain basal renal vascular resistance. 
 Stimulation of RyRs causes renal vasoconstriction.  To determine whether RyRs 
function in the renal vasculature in vivo, we used FK506 to stimulate RyRs.  FK506 activates 
RyRs in the same manner as cADPR, by binding and removing the inhibitory molecule 
FKBP12 or FKBP12.6 from the RyR (33).  Injection of FK506 into the renal artery caused a 
22 ± 6% constriction, compared with 5 ± 1% constriction due to vehicle alone (P=0.02; Fig. 
2.5).  These results demonstrate the presence of functional RyRs, capable of contracting the 
renal vasculature upon activation. 
 RyRs mediate Ang II- and NE-induced renal vasoconstriction.  To further assess the 
physiological importance of RyRs in the renal vasculature, we determined the extent to 
which RyRs are involved in acute vasoconstriction produced by Ang II and NE.  Ruthenium 
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red was used to inhibit RyRs.  Ang II produced a 30 ± 5% decrease in RBF during control 
conditions (Fig. 2.6). Intrarenal infusion of ruthenium red did not alter basal RBF or MAP 
after 3 min, but inhibited RBF responses to Ang II in a dose-dependent manner. The highest 
dose attenuated Ang II- mediated renal vasoconstriction to a 15 ± 2% decrease in RBF 
(P<0.01).  The inhibitory effect of ruthenium red was reversible after 10 min. 
 Similarly, ruthenium red attenuated NE-induced renal vasoconstriction.  NE produced 
a 27 ± 4% decrease in RBF in the control period (Fig. 2.7).  The highest dose of ruthenium 
red tested decreased the renal vascular response to 11 ± 2% (P<0.01).  Responses to NE 
returned to normal after 10 min.  We conclude that RyRs contribute to GPCR-mediated renal 
vasoconstriction in vivo. 
 RyRs mediate voltage-gated Ca2+ channel-induced renal vasoconstriction.  Due to the 
apparent similarity of RyR involvement in the vascular effects of Ang II and NE, we tested 
whether RyRs contribute to L-type voltage-gated Ca2+ channel-induced renal 
vasoconstriction.  Intrarenal injection of the L-type channel agonist BayK-8644 produced a 
78 ± 7% decrease in RBF (Fig. 2.8).  This response was inhibited 63% by ruthenium red 
(P<0.001), resulting in an attenuated RBF response of 29 ± 4%.  Bay-K8644-induced RBF 
responses returned to normal after 10 min.  These results demonstrate involvement of RyRs 
in renal vascular responses elicited by stimulating Ca2+ entry. 
 Genetic disruption of ADPR cyclase in mice leads to impaired renal vascular 
responses to Ang II and NE.  To determine the effect of chronic inhibition of ADPR cyclase 
on Ang II- and NE-induced renal vasoconstriction, we compared RBF responses to Ang II 
and NE injected iv in wild type and CD38-/- mice.  CD38-/- mice showed impaired renal 
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vascular reactivity to both Ang II and NE.  Whereas Ang II and NE produced 30 ± 8% and 
37 ± 6% decreases in RBF in wild type animals, mice lacking CD38 showed 8 ± 1% and 19 ± 
4% decreases in RBF, respectively (Fig. 2.9, P<0.05 for both).  These data indicate that 
mutation of the ADPR cyclase, CD38, results in attenuated renal vascular responses to Ang II 
and NE in vivo.  Furthermore, our results demonstrate the requirement for ADPR cyclase in 
renal vasoconstriction is not specific to rats, but exists in multiple species. 
E.  DISCUSSION 
Our study is the first to provide information about the functional importance of the 
ADPR cyclase/RyR signaling pathway in the regulation of renal vascular resistance in vivo.  
Collectively, our results support the notion that ADPR cyclase and its intermediates are 
linked to renal vasoconstriction through activation of RyR and enhancement of Ca2+-induced 
Ca2+ release (CICR).  Results obtained using pharmacological inhibitors and a knockout 
mouse model indicate that ADPR cyclase and RyRs mediate the renal vascular actions of 
Ang II and NE.  In addition, the ADPR cyclase/RyR system contributes to renal 
vasoconstriction elicited by activation of Ca2+ entry through L-type channels independent of 
GPCR associated second messengers, providing additional insight into the importance of this 
signaling system in Ca2+ metabolism and contraction of resistance arterioles in vivo.  Our 
study reinforces our previous results showing that the ADPR cyclase/RyR pathway 
contributes significantly to the regulation of [Ca2+]i in individual afferent arterioles (64; 61) 
and extends these findings to the regulation of vascular resistance in the intact renal 
microcirculation during basal conditions as well as during GPCR agonist-induced renal 
vasoconstriction.  
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 Basal levels of ADPR cyclase contribute to the maintenance of tonic renal vasomotor 
tone under resting conditions. The vasodepressor effects of nicotinamide have long been 
recognized (113; 238).  More recent work shows that the mechanism is related to ADPR 
cyclase inhibition (12; 88).  In the present study, infusion of high dose nicotinamide into the 
renal artery produced a significant increase in RBF while MAP is stable, indicative of renal 
vasodilatation.  The dilation observed is rapid in onset, increases over the observation period, 
and is readily reversible. One possible explanation for this biphasic response is that the large 
immediate increase in RBF reflects inhibition of ADPR cyclase and associated attenuation of 
downstream Ca2+ signaling.  The secondary, slower progressive increase in RBF may 
represent a component of Ca2+ signaling affected by prolonged period of low [Ca2+]i caused 
by depletion of SR stores, associated with vasodilatation.   
 Basal activities of ADPR cyclase and RyRs are functionally important in the renal 
vasculature as evidenced by their contribution to the acute renal constrictor response to L-
type Ca2+ channel activation.  Nicotinamide and ruthenium red inhibited a significant portion 
of the renal vasoconstriction induced by the L-type Ca2+ channel agonist Bay-K8644 which 
was not dependent on GPCR activation of ADPR cyclase.  It is not clear whether the Bay-
K8644 response involves direct ADPR cyclase activation or the presence of basal tonic levels 
of cADPR and/or NAADP, which are sufficient to enhance RyR receptor activation by Ca2+ 
entry initiated by Bay-K8644.  The latter seems more plausible; participation of ADPR 
cyclase activity in vasoconstriction induced by activation of L-type Ca2+ channels is most 
likely due to the impact of cADPR on CICR.  Biochemical studies show that cADPR greatly 
sensitizes RyR to [Ca2+]i (175; 223) and acts predominately, if not exclusively, by this 
mechanism (159) and that tonic ADPR cyclase activity is present in coronary artery 
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homogenates (87; 88).  Tonic activity of ADPR cyclase seems sufficient to provide cADPR 
to sensitize RyRs to respond to small changes in [Ca2+]i, resulting in CICR and amplification 
leading to increased RVR.  This idea is supported by recent data showing that specific 
inhibition of cADPR with 8Br-cADPR attenuates KCl-induced increases in [Ca2+]i in isolated 
afferent arterioles (66).  
 RyRs are generally considered downstream targets for the products of ADPR cyclase 
in other vascular beds (4; 63; 87).  cADPR activates RyRs by removing FK506 binding 
proteins (FKBPs) that associate with the receptor (184; 239). When used clinically as an 
immunosuppressant, FK506 often produces a side-effect of hypertension (191; 235).  In the 
present study, FK506 caused pronounced renal vasoconstriction when injected into the renal 
artery, demonstrating the functional importance of RyRs in acute regulation of the renal 
circulation.  Aside from effects on RyRs, FK506 also inhibits the actions of the calcium 
activated protein phosphatase calcineurin.  Calcineurin is present in VSMC and functions in 
gene expression (183).  Effects of calcineurin in VSMC and other cell types, however, are 
primarily elicited through activation of transcription factors including nucleated factor of 
activated T-cells (NFAT) and changes in protein levels (108; 229).  Such changes mediate 
long-term renal effects of FK506 and likely contribute to FK506-induced hypertension.  The 
nearly instantaneous effect of FK506 on RBF seen in our study, however, is too rapid to be 
dependent on changes in gene expression and is therefore not likely due to calcineurin 
inhibition. 
 Our in vivo data verify previously reported effects of FK506 on blood flow in isolated 
preparations.  FK506 is reported to decrease RBF by 23% in an in situ autoperfused rat 
kidney(10) and contract isolated rat and human renal arteries (217).  To our knowledge, only 
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one other study has investigated the effects of acute FK506 infusion on RBF in vivo (252).  
In this study, FK506 was continuously administered iv in the presence of L-NAME for 1 hr 
and resulted in a 47% decrease in RBF.  Our study shows that effects of FK506 on RBF are 
localized to the kidney and occur when nitric oxide is present. 
The actions of ADPR cyclase and RyRs are responsible for a majority of acute renal 
vasoconstriction elicited by Ang II and NE.  We found that either nicotinamide or ruthenium 
red blocked up to 70% of agonist-induced renal vasoconstriction without changing baseline 
MAP.  Furthermore, we show that CD38-/- mice have significantly attenuated renal vascular 
responses to Ang II and NE.  It is unclear whether ADPR cyclase is directly activated by Ang 
II and NE, or if basal levels of cADPR and/or NAADP enhance renal vascular responses to 
Ang II and NE.  The previously reported literature has suggested that ADPR cyclase 
contributes to agonist-induced vasoconstriction.  ADPR cyclase, cADPR, and RyRs 
participate in Ang II-mediated increases in [Ca2+]i in preglomerular resistance arterioles (61), 
those triggered by KCl-induced depolarization (66) and constrictor responses to NE are 
attenuated in aortic rings of CD38-/- mice (173).  RyRs have also been implicated in NE 
signaling in vascular myocytes (21).  Our studies add to this pool of knowledge by 
demonstrating a functional role of ADPR cyclase and RyRs in the renal vasculature in vivo.  
Further studies are required to clarify the relative importance of agonist-induced activation of 
this signaling pathway as compared to basal levels sufficient to accommodate CICR.   
It is interesting to note that we observed a trend towards greater renal vascular 
responses to Ang II and NE during recovery after acute dose-dependent inhibition of the 
ADPR cyclase/RyR pathway.  Sustained inhibition of Ca2+ mobilization may have resulted in 
accumulation of Ca2+ in SR stores that were unmasked as exaggerated Ca2+ release and 
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agonist-induced contraction during the recovery period.  This exaggerated response was 
particularly prominent in NE experiments involving nicotinamide. 
Our results suggest that ADPR cyclase and RyRs may function importantly in both 
afferent and efferent arterioles.  Activation of L-type Ca2+ channels is likely to increase renal 
vascular resistance by a primary action of Ca2+ entry in the preglomerular vasculature, 
predominantly afferent arterioles (26; 77).  In contrast, efferent arterioles appear to have few, 
if any, L-type Ca2+ channels that are activated by Bay-K8644 or KCl-induced depolarization 
(26; 77; 157).  Our results indicate that nicotinamide and ruthenium red inhibit more than 
50% of the renal vascular response to Bay-K8644.  In this regard, our results highlight the 
functional role of ADPR cyclase/RyR signaling in afferent arteriolar-mediated renal 
vasoconstriction initiated by Ca2+ entry. 
ADPR cyclase may contribute to efferent arteriolar constriction as well.  Earlier work 
on isolated rat afferent arterioles indicates an important role of the ADPR cyclase/RyR 
system in Ang II- and ET-1-induced increases in [Ca2+]i (65; 61).  The importance of this 
system in Ca2+ signaling in the efferent arteriole is unknown.  It is well accepted that the 
major resistance sites responsible for regulation of RBF are the small diameter afferent and 
efferent arterioles and that Ang II and NE constrict both sets of glomerular arterioles.  The 
relative strength of contraction is reported to be equal (17; 227; 228), or with predominant 
effects on efferent arterioles (176).  Since these studies suggest that at least 50% of renal 
vasoconstriction takes place in the efferent arteriole, our findings that nicotinamide and 
ruthenium red inhibit 50-70% of Ang II- and NE-induced contraction raise the question that 
the ADPR cyclase/RyR signaling pathway may contribute to efferent arteriolar constriction 
as well. 
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 In summary, we present RBF evidence that the ADPR cyclase/RyR pathway plays an 
important physiological role in the regulation of basal renal vascular resistance during resting 
conditions and in acute renal vasoconstrictor responses elicited by Ang II, NE and Bay-
K8644 injection into the renal artery.  This is the first study to document the functional 
importance of the ADPR cyclase/RyR pathway in the vasculature in vivo.  Intrarenal infusion 
of high-dose nicotinamide to inhibit ADPR cyclase activity produces renal vasodilatation as 
evidenced by increased RBF and reduced RVR in the absence of a change in MAP.  Lower 
doses of nicotinamide that did not affect basal RBF markedly attenuate the acute renal 
vasoconstriction produced by intrarenal injection of Ang II, NE or Bay-K8644.  In all three 
cases, the constriction appeared to be mediated by RyR as ruthenium red reduced the renal 
microcirculatory response to each agonist.  Renal vascular reactivity to Ang II and NE was 
markedly attenuated in mice lacking the ADPR cyclase CD38, solidifying conclusions of 
vascular signaling based on nicotinamide inhibition of ADPR cyclase in rats.  The Bay-
K8644 studies provide insight into the functional importance of the ADPR cyclase/RyR 
pathway in Ca2+ signaling and CICR in renal vasoconstriction that occurs independent of 
GPCRs.  
  
  
Figure 2.1.  A:  Representative recording of RBF (black) and MAP (gray) after Ang II 
injection at time zero during infusion of saline (top) or nicotinamide (bottom).  
maximum decrease in RBF in response to Ang II during control (ctrl), increasing doses of 
nicotinamide, or recovery period (rec).  n=8;  *:  P<0.001, †: P<0.01 vs. control.
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Figure 2.2.  A:  Recording of RBF (black) and MAP (gray) responses to NE injection at time 
zero during infusion of saline (top) or nicotinamide to inhibit ADPR cyclase (bottom).  
Average maximum percent change in RBF in response to NE during the control period (ctrl)
in the presence of increasing doses of nicotinamide, or during recovery period (rec).  n=8.  *:  
P<0.05 vs. control. 
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 Figure 2.3.  A:  Typical tracing of RBF (black) and MAP (gray) in response to intrarenal 
injection of the L-type voltage
infusion of saline (top) or nicotinamide (6 mg/kg/min, bottom).  
decrease in RBF in response to BayK
nicotinamide infusion, n=5.  *:  P<0.02 vs. 
44 
 
 
 
-gated Ca2+ channel agonist, Bay-K8644 (2.5 µg) during 
B:  Average maximum 
-8644 before (ctrl), during (6), or after (rec) 
control.   
  
Figure 2.4.  A:  Percent of initial RBF (closed circles) and MAP (open circles) during 3 min 
infusion of nicotinamide at 6 mg/kg/min (n=5).  
and MAP (open circles) during 20 min infusion of 
*P<0.005 vs. initial. 
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B:  Percent of initial RBF (closed circles) 
nicotinamide at 12 mg/kg/min (n=6).  
  
 
Figure 2.5.  A:  Original recording of changes in RBF (black) and MAP 
injection of FK506 to stimulate RyRs (250 µg, bottom) or vehicle (top).  
maximum percent change in RBF in response to FK506 or vehicle (n=8).  *:  P=0.021 vs. 
vehicle alone. 
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B:  Average 
  
Figure 2.6.  A: Tracing of changes in RBF (black) and MAP (gray) after Ang II injection 
given at time zero during infusion of saline (top) or ruthenium red (bottom).  
maximum decrease in RBF in response to Ang II in the presence of increasing doses of 
ruthenium red or during recovery period (rec).  n=8.  *:  P<0.01 vs control.
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B:  Average 
 Figure 2.7.  A:  Recording of changes in RBF (black) and MAP (gray) after NE injection at 
time zero during infusion of saline (top) or ruthenium red to inhibit RyRs (126 µg/kg/mi
bottom).  B:  Average maximum percent change in RBF in response to NE in the presence of 
increasing doses of ruthenium red or during recovery period (rec).  n=8.  *:  P<0.01 vs. 
control.   
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Figure 2.8.  A:  Representative recording of RBF (black) and MAP (gray) after injection of 
Bay-K8644 during infusion of saline (top) or ruthenium red (bottom).  
maximum decrease in RBF in response to BayK
(rec) ruthenium red infusion, n=7.  *:  P<0.001 vs. control.
49 
 
 
 
B:  Average 
-8644 before (ctrl), during (126), or after 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9.  Average decrease in RBF in response to systemically injected Ang II and NE in 
wild type mice (white bars, WT) and mice lacking CD38 (black bars), n=6 for each group.  *:  
P<0.05 vs. wild type. 
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CHAPTER III 
 
ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-
induced renal vasoconstriction in vivo 
 
 
 
 
 
 
 
 
 
Reprinted with permission from American Journal of Physiology Renal Physiology 295:  
F360-368.  Copyright © 2009 by the American Physiological Society.   All rights of 
reproduction of any form reserved. 
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A.  ABSTRACT 
 ADP ribosyl cyclase (ADPR cyclase) and ryanodine receptors (RyR) participate in 
calcium transduction in isolated afferent arterioles.  We hypothesized that this signaling 
pathway is activated by ETA and ETB receptors in the renal vasculature to mediate 
vasoconstriction in vivo.  To test this, we measured acute renal blood flow (RBF) responses 
to ET-1 in anesthetized rats and mice in the presence and absence of functional ADPR 
cyclase and/or RyR.  Inhibitors of ADPR cyclase (nicotinamide) or RyR (ruthenium red) 
reduced RBF responses to ET-1 by 44% (P<0.04 for both) in Sprague-Dawley rats.  Mice 
lacking the predominant form of ADPR cyclase (CD38-/-) had RBF responses to ET-1 that 
were 47% weaker than those seen in wild type mice (P=0.01).  Selective ETA receptor 
stimulation (ET-1 + BQ788) produced decreases in RBF that were attenuated by 43% and 
56% by nicotinamide or ruthenium red, respectively (P<0.02 for both).  ADPR cyclase or 
RyR inhibition also reduced vasoconstrictor effects of the ETB receptor agonist sarafotoxin 
S6c (77% and 54%, respectively, P<0.02 for both).  ETB receptor stimulation by ET-1 + the 
ETA receptor antagonist BQ123 elicited responses that were attenuated by 59% and 60% by 
nicotinamide and ruthenium red, respectively (P<0.01 for both).  Nicotinamide attenuated 
RBF responses to S6c by 54% during inhibition of nitric oxide synthesis (P=0.001).  We 
conclude that in the renal microcirculation in vivo:  1) ET-1-induced vasoconstriction is 
mediated by ADPR cyclase and RyR, 8) both ETA and ETB receptors activate this pathway, 
and 3) ADPR cyclase participates in ETB receptor signaling independent of NO. 
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B.  INTRODUCTION 
 Endothelin-1 (ET-1) is one of the most potent vasoconstrictors identified to date.  
Dysfunction in ET-1 regulation or receptor signaling has been implicated in several 
cardiovascular diseases including atherosclerosis, coronary artery disease, congestive heart 
failure, cerebrovascular disease, and systemic and pulmonary hypertension  and in acute and 
chronic renal disease (82; 139; 160; 204; 213; 214). ET-1 is thought to act primarily in a 
local paracrine fashion in the vasculature, being secreted from endothelial cells abluminally 
to act on nearby vascular smooth muscle cells (VSMC).  Circulating levels of ET-1 appear to 
have a relatively minor influence on vascular tone.  In this regard, it has been proposed that 
ETB receptors bind circulating ET-1 and provide a clearance function (214). 
 The renal vasculature is particularly responsive to ET-1 (140; 201).  Acute 
intravenous administration of ET-1 decreases in renal blood flow (RBF) in animals (110; 
140) and increases renal vascular resistance in humans without affecting arterial pressure 
(202).  The effects of ET-1 on RBF are due to contraction of preglomerular arteries and 
afferent and efferent arterioles as has been shown in specialized isolated vascular 
preparations (55; 120; 143) and in vivo (140; 201).  Although ET-1 does not affect steady-
state RBF autoregulation, ET-1 stimulation of NO production alters the dynamics of the 
preglomerular myogenic response (220). 
 ET-1 signals via two G protein coupled receptors(GPCR): ETA and ETB (160; 194; 
214).  Stimulation of ETA or ETB receptors results in elevation of cytosolic calcium 
concentration [Ca2+]i.  ET-1 stimulates the production of inositol 1,4,5-triphosphate (IP3) and 
1,2-diacylglycerol (DAG).  IP3 can bind to IP3Rs on the sarcoplasmic reticulum (SR) to 
54 
 
release Ca2+ while DAG activates PKC, resulting in downstream activation of myosin light 
chain kinase and cell contraction. 
 Most VSMC have SR with Ca2+ sensitive ryanodine receptors (RyR) that participate 
in Ca2+ mobilization.  RyR can be activated by second messengers produced by the enzyme 
ADP ribosyl cyclase (ADPR cyclase) (1; 272).  We have previously observed that this ADPR 
cyclase/RyR signaling pathway plays a significant role in mediating responses to Ang II in 
Ca2+ signaling in isolated afferent arterioles (64) and renal vasoconstriction in vivo (241).  
However, little is known about which GPCRs activate this particular second messenger 
system in specific vascular beds.  Participation may depend on vessel size and function and 
vascular bed.  For example, it appears that thromboxane A2 (TxA2) signaling through the TP 
receptor does not involve ADPR cyclase and RyR in isolated renal arteries (240), whereas 
ADPR cyclase inhibition dilates TxA2 preconstricted coronary arteries (88). Interestingly, 
isolated aortas from mice genetically lacking the predominant form of  ADPR cyclase 
(CD38-/-) show normal contractile responses to ET-1 but contraction to the α-adrenergic 
receptor agonist phenylephrine is weaker than that seen in wild type mice (173).  We find 
that α-adrenergic receptor-induced renal vasoconstriction is dependent on ADPR cyclase and 
RyR in vivo (241).   
 Evidence indicates that ET-1 activates ADPR cyclase in VSMC of coronary, renal, 
mesenteric, and pulmonary beds.  The ADPR cyclase inhibitor nicotinamide attenuates 
contraction of mesenteric arteries elicited by ET-1 (90).  Evidence implicates both second 
messengers produced by ADPR cyclase in VSMC responses to ET-1.  Incubation of coronary 
arterial myocytes with ET-1 stimulates production of the ADPR cyclase metabolite nicotinic 
acid ADP (NAADP) (274). In pulmonary arterial VSMC, Ca2+ responses to ET-1 are 
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attenuated by bafilomycin A1, an inhibitor of NAADP-induced Ca2+ release (135).  Selective 
inhibition of cyclic ADP ribose, a second metabolite formed by ADPR cyclase with 8Br-
Cadpr attenuates Ca2+ responses to ET-1 in rat renal afferent arterioles (65).   
 To our knowledge, the importance of ADPR cyclase/RyR signaling in mediating ET-
1-induced vasoconstriction has not been studied in vivo in any vascular bed.  Due to the 
emerging importance of ADPR cyclase in GPCR signaling, we hypothesized that ADPR 
cyclase and RyR contribute to renal vascular responses to ET-1 in vivo.  We determined the 
importance of this signaling pathway in responses to ETA and ETB receptor stimulation in the 
renal microcirculation. 
C.  MATERIALS AND METHODS  
 Sprague Dawley rats, wild type C57BL6 mice, and CD38-/- mice on a C57BL6 
background were obtained from our Chapel Hill breeding facility.  CD38-/- mice and wild 
type control breeder pairs were originally obtained from Dr. Frances Lund (Trudeau Institute, 
Saranac Lake, NY) and Jackson Labs (Bar Harbor, ME), respectively.  All animals were 
cared for and used in accordance with institutional guidelines.  Protocols were approved by 
the local Institutional Animal Care and Use Committee.  Animals were anesthetized using 
sodium pentobarbital (Nembutal, 50-60 mg/kg body wt ip for rats, 80-90 mg/kg body wt ip 
for mice, Abbott, Chicago, IL). 
 Surgical Procedures in Rats- The surgical preparation for measurement of RBF in 
rats was performed as is standard in our laboratory (129; 127; 241).  The right femoral artery 
was catheterized using a PE50 catheter for continuous measurement of mean arterial pressure 
(MAP) via a pressure transducer (Statham P23 dB).  The right femoral vein was catheterized 
using three PE10 catheters for infusio
min=body wt (g)/4, then reduced to 10 µl/min for the remainder of the experiment), 
maintenance of anesthesia using sodium pentobarbital as required, and injection of 
L-arginine methyl ester (L-NAME) when applicable.  The bladder was catheterized and 
tracheotomy was performed.  A curved PE50 catheter was inserted into the left common 
iliac, passed up the aorta, and positioned such that the tip of the catheter was facing but not 
obstructing the left renal artery for administration of pharmacological agents.  An ultrasonic 
flow transducer was placed around the left renal artery to measure RBF (model 1RB, 
Transonic, Ithaca, NY). 
 Surgical Procedures in Mice
from those previously developed in our laboratory 
into the right femoral artery for continuous measurement of MAP via a pressure transducer 
(Statham P23 dB).  Pulled PE10 catheters were inserted into a femoral vein for iv 
administration of bovine serum albumin (2.4%, 10 µl/min for the duration of t
and ET-1.  A tracheotomy was performed and the bladder catheterized.  The left renal artery 
was freed from the renal vein, and RBF was measured by an ultrasonic flow transducer 
(0.5V, Transonic, Ithaca, NY).
 Assessment of Renal Vascular Rea
ng) and S6c (7.5 ng) were given directly into the renal artery in the manner previously 
described (129; 127). Previous studies show that RBF and MAP responses to ET
recover, albeit slowly, over 30 min 
were given to the same animal. In mice, a 10 µl bolus of ET
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femoral vein.  L-NAME (25 mg/kg in 1 ml/kg 0.9% NaCl) was injected into a femoral vein 
of rats 30 min prior to the start of an experiment.  
 Ruthenium red (126 µg/kg/min), an inhibitor of RyR, nicotinamide (6 mg/kg/min), an 
ADPR cyclase inhibitor, BQ123 (18.64 µg/kg/min), an ETA receptor antagonist, and BQ788 
(18.64 µg/kg/min), an ETB receptor antagonist, were infused into the renal artery 3 min prior 
and 5 min following ET-1 or S6c injection.  These doses of nicotinamide and ruthenium red 
were based on an earlier study in which we established effective inhibition of Ang II- and 
NE- induced renal vasoconstriction while neither agent affected basal RBF or MAP (241).  It 
is important to note that complete inhibition was not reached at the doses used in the present 
study as higher amounts are known to produce more pronounced inhibition of ADPR cyclase 
as evidenced by frank renal vasodilatation (241).  Following the inhibitory period, the animal 
was allowed to recover for 10 min prior to a final assessment of reactivity.  In all cases, the 
response during the recovery period returned to the control level indicating rapid reversibility 
of inhibitors and stability of the preparation.  The doses of ET receptor antagonists are known 
to effectively antagonize ETA and ETB receptors selectively (129).  To avoid possible 
overlapping effects, each rat received only one inhibitor (nicotinamide or ruthenium red). 
 Pharmacological Agents- ET-1, L-NAME, nicotinamide, and ruthenium red were 
purchased from Sigma Aldrich (St. Louis, MO).  S6c, BQ123, and BQ788 were obtained 
from American Peptide Company (Sunnyvale, CA).  All pharmacological agents were 
dissolved in 0.9% NaCl. 
 Data Analysis- Data were collected using Labtech Notebook software and graphs 
were created using SigmaPlot software.  Statistical analyses of differences in RBF responses 
58 
 
between control and experimental periods were performed by a paired student's t-test using 
SigmaStat software. 
D.  RESULTS 
 Results are reported for a total of 58 male Sprague-Dawley rats averaging 7.3 ± 0.1 
weeks of age.  In rats not treated with L-NAME, RBF and MAP were 3.8 ± 0.2 ml/min/g 
kidney wt and 100 ± 4 mmHg, respectively.  L-NAME treated animals showed an increased 
MAP (145 ± 3 mmHg, P<0.001) and decreased RBF (3.0 ± 0.3 ml/min/g, P<0.05). 
 ET-1-induced renal vasoconstriction is dependent on ADPR cyclase activation and 
RyR.  To determine whether ADPR cyclase mediates renal vascular responses to ET-1, we 
gave intrarenal bolus injections of ET-1 to rats before and during intrarenal infusion of the 
ADPR cyclase inhibitor nicotinamide.  ET-1 injection into the renal artery decreased RBF by 
31 ± 3% (Fig. 3.1).  This response was impaired in the presence of nicotinamide such that 
only a 17 ± 3% decrease in RBF was produced by the same amount of ET-1, a response that 
was decreased 45% from that observed in the control period (P<0.01).   
 To test the importance of RyR, we compared renal vascular responses to ET-1 in the 
presence or absence of the RyR inhibitor ruthenium red in other animals.  The 29 ± 4% 
decrease in RBF was induced by ET-1 under control conditions was attenuated by ruthenium 
red. ET-1 produced a 16 ± 3% decrease in RBF in the experimental period (Fig. 3.2).  Thus, 
both ADPR cyclase and RyR appear to play a role in acute ET-1 responses in the renal 
microcirculation of normotensive rats.  
 Renal vascular responses to ETA receptor stimulation are mediated by ADPR cyclase 
and RyR.  ETA and ETB receptors are both present in the renal microvasculature and mediate 
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total RBF responses to ET-1 (48; 89; 129).  As a result, we asked whether the importance of 
ADPR cyclase in the renal hemodynamic actions of ET-1 is selectively dependent on one ET 
receptor subtype over the other.   
 To specifically stimulate ETA receptors, we injected ET-1 into the renal artery of rats 
in the presence of the selective ETB receptor antagonist BQ788.  In the absence of 
nicotinamide, the combination of ET-1 + BQ788 decreased RBF by 50 ± 5% (Fig. 3.3).  
When nicotinamide was infused into the renal artery to inhibit ADPR cyclase, the constrictor 
response to ETA receptor stimulation was markedly attenuated.  During ADPR cyclase 
inhibition, ET-1 + BQ788 decreased RBF by 28 ± 3%, an attenuated response compared to 
ET-1 + BQ788 given without nicotinamide (P<0.01).  Similarly, RyR inhibition with 
ruthenium red attenuated the acute RBF response to ET-1 + BQ788 from 56 ± 10% to 25 ± 
4% (P<0.02, Fig. 3.4).  Together, these data demonstrate a significant role for ADPR cyclase 
and RyR in ETA receptor-mediated renal vasoconstriction.   
 Vasoconstrictor responses to ETB receptor stimulation are dependent on activation of 
ADPR cyclase and RyR.  To test the importance of ADPR cyclase and RyR in ETB receptor 
signaling, we injected the specific ETB receptor agonist sarafotoxin S6c into the renal artery.  
In other animals, a combination of the ETA antagonist BQ123 and ET-1 was tested.  When 
given into the renal artery, S6c and ET-1 + BQ123 reduced RBF by 22 ± 4% (Fig. 3.5) and 
13 ± 2% (Fig. 3.6), respectively.  Thus, as has been previously demonstrated (129), we found 
that ETB receptor stimulation elicits net renal vasoconstriction.  Nicotinamide markedly 
inhibited the vascular effects of both S6c and ET-1 + BQ123 such that only a 5 ± 2% 
decrease in RBF was observed in both groups (P<0.01 for both).  These findings suggest that 
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ADPR cyclase participates in acute renal vasoconstrictor responses to selective ETB receptor 
stimulation in a healthy rat kidney. 
 Other experiments indicate that RyR participate in ETB receptor responses in the renal 
vasculature in vivo.  Prior to administration of ruthenium red, S6c and ET-1 + BQ123 
decreased RBF by 16 ± 3 (Fig. 3.7) and 9 ± 1% (Fig. 3.8), respectively.  In the same animals, 
ruthenium red attenuated RBF changes during ETB receptor stimulation.  During RyR 
inhibition in these groups, S6c and ET-1 + BQ123 decreased RBF by 7 ± 2% and 4 ± 1%, 
respectively (P<0.02 for both), reductions of approximately 50%. 
 ADPR cyclase activation by ETB receptors is independent of nitric oxide.  In addition 
to vasoconstrictor properties of ETB receptors on VSMC, ETB receptors are present on 
endothelial cells of renal vessels (114; 253).  When stimulated, these receptors produce NO 
and other dilator agents that buffer ET-1-induced renal vasoconstriction (111; 127).  Since 
interactions between NO and ADPR cyclase have been reported in both VSMC and 
endothelial cells of non-renal arteries (266; 276), we asked whether the effects of 
nicotinamide on ETB receptor-induced renal vasoconstriction persist in the absence of NO 
production.  To test this, we evaluated the effect of ADPR cyclase inhibition on S6c 
responses during inhibition of NO synthase using L-NAME. During
 
L-NAME infusion, S6c 
decreased RBF by 28 ± 3% (Fig. 3.9).  Nicotinamide attenuated the S6c response such that a 
13 ± 2 % decrease in RBF was observed in the experimental period (P<0.005).  These results 
suggest that ADPR cyclase activation by ETB receptor stimulation occurs in the absence as 
well as the presence of NO. 
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 RBF responses to ET-1 are impaired in mice with decreased ADPR cyclase activity.  
The importance of ADPR cyclase in renal vascular responses to ET-1 was assessed in mice 
lacking the predominant form of ADPR cyclase (CD38).  ET-1 injected iv produced a 19 ± 
3% decrease in RBF in wild type mice, compared with a 10 ± 1% decrease in CD38-/- mice 
(P<0.02, Fig. 3.10).  This finding in mice reinforces our pharmacological studies on rats 
demonstrating the importance of ADPR cyclase in renal vascular responses to ET-1 in the 
rat.  
E.  DISCUSSION 
 Our study is the first to demonstrate a dependence of ET-1 signaling on ADPR 
cyclase activation and RyR in the microcirculation of any organ in rats and mice in vivo.  
Acute ET-1-induced vasoconstriction in the kidney is critically dependent on the activity of 
ADPR cyclase and RyR.  This conclusion is based on results obtained using pharmacological 
inhibitors and a knockout mouse.  We find that both ETA and ETB receptors utilize the ADPR 
cyclase/RyR signaling pathway to produce vasoconstriction of renal resistance arterioles in 
rats.  Experiments in mice demonstrate the importance of one ADPR cyclase family member 
in particular, CD38, in ET-1-induced renal vasoconstriction.  Our study extends previous 
work establishing the importance of ADPR cyclase and RyR in mediating [Ca2+]i responses 
to ET-1 receptor stimulation in isolated renal afferent arterioles (65) and provides new 
information regarding the importance of this pathway in an integrated, natural environment. 
 We found that ADPR cyclase and RyR mediate a significant portion of acute renal 
vasoconstriction produced by ET-1.  In our rat studies, pharmacological agents used to 
inhibit both ADPR cyclase and RyR attenuated renal vasoconstrictor responses to ET-1 by 
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~45%.  Nicotinamide and ruthenium red are widely used to inhibit ADPR cyclase and RyR, 
respectively.  Nicotinamide is a byproduct of ADPR cyclase conversion of NAD+ to cADPR 
and NADP+ to NAADP (1; 145) and nicotinamide shifts the ADPR cyclase reactions to 
produce relatively small amounts of NAD+ and NADP+ rather than adding significantly to 
the pool of cADPR and NAADP.  Although nicotinamide may also inhibit poly (ADP-ribose) 
polymerase-1 (PARP-1)  (260), this is unlikely to be a major factor in our studies since 
PARP-1 is generally activated only under incidences of extreme stress (8) and our animals 
were closely monitored to ensure the most physiological conditions possible.  As a 
commonly used inhibitor of RyR, ruthenium red binds directly to RyR, causing a 
conformational change that renders the channel inactive (161).  Ruthenium red may also 
inhibit Ca2+-activated K+ channels (BKCa) (22; 161), known to be present in renal 
microvessels (162).  If this were the primary action, however, ruthenium red would be 
predicted to enhance vasoconstriction rather than oppose it as is seen in our study.   
 Our rat results were reinforced by studies on mice lacking the predominant form of 
ADPR cyclase (CD38-/-).  Three forms of ADPR cyclase are known to exist:  the non-
mammalian ADPR cyclase of the sea hare Aplysia californica and the two mammalian 
ADPR cyclases lymphocyte antigen CD38, and bone marrow stromal cell surface antigen 
BST-1 (CD157) (215).  Whereas CD157 is present primarily on immune cell types and is 
upregulated during periods of stress, CD38 is more constitutively expressed and is expressed 
in several tissues (74).  Isolated aortas without intact endothelium from CD38-/- mice have 
impaired responses to phenylephrine, suggesting a vasoconstrictor role of CD38 linked to α-
adrenoceptors  (173).  It is noteworthy that another form of ADPR cyclase sensitive to 
retinoic acid may exist in VSMC, although this form is poorly characterized (50).  In an 
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earlier study, we reported weaker than normal acute renal vascular responses to Ang II and 
norepinephrine in CD38-/- mice, suggesting that CD38 exists in resistance arterioles and 
mediates vasoconstriction in the kidney triggered by AT1 and adrenoceptors (241).  
Presently, we found that mice deficient in CD38 show attenuated renal vascular responses to 
iv injection of ET-1, supporting the notion that ADPR cyclase mediates acute ET-1-induced 
renal vasoconstriction in the mouse. 
 ET-1 responses were attenuated by 45% in the presence of either nicotinamide or 
ruthenium red.  Similarly, responses to ET-1 in CD38-/- mice were 47% less than in wild 
type controls.  Collectively, these results indicate that the ADPR cyclase/RyR signaling 
pathway accounts for roughly one-half of acute vasoconstriction of resistance arterioles in the 
kidney in response to ET-1.  Previous in vitro results indicate that IP3 and its receptor play an 
important role in mediating [Ca2+]i responses to ET-1 in renal microvessels (9; 105).  
Although one cannot discern from the current data whether the contribution of the ADPR 
cyclase and IP3 pathways to ET-1-induced renal vasoconstriction work independently, it is 
probable that a synergistic effect exists between these two signaling mechanisms.  RyR are 
Ca2+ sensitive receptors that can amplify [Ca2+]i from any source.  Ca2+ release from IP3Rs on 
the SR may activate nearby RyR by Ca2+-induced Ca2+ release (CICR).  cADPR may also 
contribute to the amplification of IP3R signaling since cADPR sensitizes RyR to CICR.  In 
addition to cADPR, ET-1 stimulation of ADPR cyclase may produce NAADP in VSMC.  
Ca2+ exiting from lysosomal stores via stimulation of NAADP receptors may also activate 
RyR to cause CICR (135).  It is noteworthy that we used concentrations of pharmacological 
agents that produced less than maximal inhibition of their intended targets, so the observed 
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degree of inhibition in rats represents a conservative estimate of the involvement of ADP 
ribosyl cyclase and RyR in the integrated renal responses. 
 Large systemic arteries predominantly express ETA receptors on VSMC and ETB 
receptors on endothelial cells (214).  In many vascular beds, ETB receptors are also expressed 
on venous VSMC (194).  In the kidney, ETA receptor stimulation on VSMC produces 
vasoconstriction (129; 127).  ETB receptor stimulation on endothelial cells leads to 
production of the vasodilator NO (127; 214) whereas ETB receptors on VSMC elicit 
vasoconstriction (55; 120; 129). This occurs both in vitro and in vivo (54; 55; 120; 140; 201).  
Since both ETA and ETB receptors mediate renal vascular responses to ET-1, we analyzed the 
contribution of the ADPR cyclase/RyR pathway to signaling by each receptor.  Our 
experimental design included selective stimulation of each receptor subtype as well as both 
together.  Antagonist specificity and dosage have been established previously in our 
laboratory (129; 127).  Both BQ123 and BQ788 effectively produce near-complete inhibition 
of ETA and ETB receptor subtypes, respectively, at the doses employed herein.  Our present 
results together with previous studies by Just et al. (129; 127) suggest that interactions must 
exist between ETA and ETB receptors since ETB receptor stimulation produces a net dilator 
effect when ETA receptors are co-stimulated, but selective stimulation of ETB receptors alone 
results in vasoconstriction.  
 Nicotinamide attenuated renal vasoconstriction produced by ETA receptor 
stimulation by ET-1 + BQ788, indicating a role for ADPR cyclase signaling in ETA receptor-
induced renal vasoconstriction in vivo.  Our previous study demonstrated a dilator effect on 
basal renal vascular resistance when a high dose of nicotinamide was administered (241).  
Importantly, the dose used in the present study was low enough to not affect resting RBF or 
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MAP.  Our in vivo results for vasomotor tone extend those for [Ca2+]i seen in isolated 
afferent arterioles (65) and testicular peritubular smooth muscle cells (11) and establish the 
importance of the ADPR cyclase signaling pathway in renal vascular responses in 
anesthetized rodents.  In individual afferent arterioles, both nicotinamide and the cADPR 
selective blocker 8Br-cADPR attenuated [Ca2+]i responses to ETA receptor stimulation (65).  
Similarly, the cADPR selective antagonist 8NH2-cADPR attenuated Ca2+ increases in 
response to ETA receptor stimulation in testicular peritubular smooth muscle cells (11).  To 
our knowledge, only one study has examined the link between ETA receptor activation and 
RyR.  This study of isolated peritubular smooth muscle cells showed that antagonist 
concentrations of ryanodine inhibited [Ca2+]i responses to ETA receptor stimulation (11).  We 
provide new information that RyR are important mediators of ETA receptor signaling in the 
renal vasculature in vivo.  By design we focused on the role of ADPR cyclase and RyRs in 
mediating ET-1-induced renal vasoconstriction and did not assess participation by other Ca2+ 
signaling pathways.  Interactions among multiple pathways are probable since cADPR has 
been shown to sensitize the RyRs to [Ca2+]i to favor CICR  (84; 269; 272).  For example, the 
[Ca2+]i and renal vasoconstrictor response initiated by Ca2+ entry through L-type Ca2+ 
channels is potentiated by basal RyR activity (66; 241). 
 We provide new evidence that the magnitude of constriction elicited by ETB receptors 
is dependent upon the activity of the ADPR cyclase/RyR signaling pathway.  Our results are 
consistent with those for [Ca2+]i experiments in peritubular smooth muscle cells in vitro(11) 
and rat cerebellum where ETB receptor signaling is dependent on cADPR and/or RyR, but 
differ from previous findings in isolated afferent arterioles showing that [Ca2+]i responses to 
S6c were not significantly diminished by nicotinamide (65). The contrast between results 
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likely reflects differences between in vitro and in vivo preparations.  Importantly, our study 
indicates that, whereas ETB receptor responses may not be mediated by ADPR cyclase in 
afferent arterioles without intact endothelium in vitro, in vivo renal constrictor responses to 
ETB receptor activation are dependent on the enzyme. 
 Unlike ETA receptors that are only found on VSMCs, ETB receptors are present on 
both VSMCs and endothelial cells and contribute to both constrictor and dilator responses 
(214).  Likewise, ADPR cyclase contributes to signaling pathways in both cell types (65; 
212), a fact that may have an impact on interpretation of our results.  Since we have 
previously seen that high concentrations of nicotinamide can increase basal RBF (241) and 
since the vasoconstrictor response to ETB is reduced rather than enhanced by nicotinamide in 
the current study as would be expected if ETB receptor-induced dilation were inhibited, we 
conclude that the bulk of the activity of ADPR cyclase in response to ET-1 is likely in the 
VSMCs rather than endothelial cells.  ADPR cyclase signaling may occur in renal endothelial 
cells.  However, inhibition of ADPR cyclase suggests a predominant action in renal VSMC.  
The role of ADPR cyclase and RyRs in ETB receptor-induced vasodilatation in the renal 
microcirculation requires futher investigation. 
 Interestingly, the attenuation of the ETB receptor agonist S6c-induced renal 
vasoconstriction by nicotinamide was significantly greater that of BQ123 + ET-1 or BQ788 + 
ET-1 (P<0.05, data not shown).  Synergy may exist between ETA and ETB receptor signaling 
pathways in the renal vasculature (120; 129).  Our data likely reflects this idea, suggesting 
that ADPR cyclase is more important in ETB receptor signaling in the presence of active ETA 
receptors.  
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 Since endothelial cells possess ETB receptors, we tested whether in vivo responses 
depend on ETB receptor-mediated NO production by investigating the contribution of ADPR 
cyclase to S6c-induced renal vasoconstriction during inhibition of nitric oxide synthase 
(NOS) activity.  We found that inhibition of S6c responses by nicotinamide occurred in the 
presence of L-NAME, indicating involvement of ADPR cyclase independent of functioning 
endothelium.  As mentioned previously, the interactions between ADPR cyclase and NO 
appear to be complex and cell-type specific.  Our data clearly show that renal 
vasoconstriction elicited by ETB receptors occurs via ADPR cyclase activation whether or 
not NO is present and add to the aforementioned suggestion that the bulk of the effect of 
ADPR cyclase inhibition in the renal vasculature in vivo is dependent on VSMCs and not 
endothelial cells.  In this regard, our results suggest that NO is probably not exerting a major 
inhibitory effect on ADPR cyclase activity in renal VSMC in vivo as has been reported for 
coronary artery VSMC in vitro(266). 
 In summary, we present RBF evidence showing that ADPR cyclase and RyR mediate 
acute renal vascular responses to ET-1 in vivo and extend our previous study of the renal 
microcirculation demonstrating the importance of the ADPR cyclase/RyR signaling pathway 
in G protein coupled receptor stimulation by Ang II and norepinephrine (241).  Ours is the 
first animal study to investigate this area in any vascular bed in vivo where complex 
interactions between cell and tissue types occur naturally.  Intrarenal infusion of 
nicotinamide or ruthenium red at doses that did not alter MAP or basal RBF attenuated RBF 
responses to ET-1.  Importantly, this was the case for responses to selective ETA and ETB 
receptor stimulation as well.  Moreover, CD38-/- mice showed attenuated RBF responses to 
ET-1.  ETB receptor dependence on ADPR cyclase was seen even in the absence as well as 
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the presence of NO production, suggesting direct effects on renal VSMC.  Our results 
provide new insight into ET-1's regulation of renal hemodynamics under normal conditions 
and have implications for regulation of renal hemodynamics in the hypertensive state when 
ET receptors are upregulated and more tonically activated (213; 214). 
  
 Figure 3.1.  A:  Average RBF responses to intrarenal ET
before (bold line) and during nicotinamide infusion into the renal artery (6 mg/kg/min, fine 
line).  B:  Average change in RBF in response to ET
(rec) nicotinamide, n=8.  *: P<0.01.
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Figure 3.2.  A:  Average RBF responses to intrarenal ET
line) and during ruthenium red infusion into the renal artery (126 µg/kg/min, fine line).  
Average RBF response to ET
n=8.  *: P<0.05. 
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Figure 3.3.  A:  Average RBF responses to intrarenal ET
BQ788 before (bold line) and during nicotinamide infusion into t
mg/kg/min, fine line).  B:  Average change in RBF in response to intrarenal ET
during infusion of BQ788 before (ctrl), during (nic), and after (rec) nicotinamide, n=9.  *: 
P<0.01.   
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Figure 3.4.  A:  Average change in RB
of BQ788 before (bold line) or during intrarenal ruthenium red infusion (126 µg/kg/min, fine 
line).  B:  Average RBF responses to ET
red), or after (rec) ruthenium red, n=7.  *: P<0.02.
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Figure 3.5.  A:  Average RBF changes over time in response to intrarenal sarafotoxin S6c 
injection before (bold line) and during nicotinamide infusion into the renal artery (6 
mg/kg/min, fine line).  B:  Average 
(nic), and after (rec) nicotinamide, n=8.  *: P<0.005.
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Figure 3.6.  A:  Average RBF changes produced by ET
ETA receptor antagonist BQ123 prior (bold line) or
(6 mg/kg/min, fine line).  B:  
BQ123 before (ctrl), during (nic), and after (rec) nicotinamide, n=12.  *:  P<0.01.
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Figure 3.7.  A:  Average RBF change in response to intrarenal injection of sarafotoxin S6c 
under control conditions (bold line) and in the presence of ruthenium red infusion into the 
renal artery (fine line, 126 µg/kg/min).  
during (ruth red), and after (rec) ruthenium red, n=8.  *: P<0.02.
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B: Average RBF responses to S6c before (ctrl), 
 
 Figure 3.8.  A:  Average RBF response to ET
BQ123 before (bold line) and during intrarenal nicotinamide infusion (6 mg/kg/min, fine 
line).  B:  Average change in RBF in response to ET
(ctrl), during (nic), and after (rec) nicotinamide, n=9.  *: P<0.01.
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Figure 3.9.  A:  RBF response to sarafotoxin S6c during
and during nicotinamide infusion into the renal artery (6 mg/kg/min, fine line).  
in RBF in response to S6c during 
nicotinamide, n=8.  *: P<0.005.
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Figure 3.10.  A:  RBF response to ET
animals.  B:  Maximum RBF responses to iv injection of ET
(WT, open bar) and mice lacking CD38 (CD38
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A.  OVERVIEW OF RESULTS 
The overall purpose of this dissertation was to determine the role, if any, of the 
ADPR cyclase signaling pathway in the regulation of renal hemodynamics.  To this end, I 
employed a variety of in vivo and in vitro techniques to demonstrate expression and 
physiological relevance of ADPR cyclase signaling in the renal vasculature.  I found that 
ADPR cyclase regulates baseline RBF and ADPR cyclase and RyR mediate in vivo 
vasoconstrictor responses to Ang II, NE, and ET-1.  Furthermore, I showed expression of two 
ADPR cyclase family members in renal preglomerular resistance arterioles and determined 
CD38 to be the family member primarily responsible for the physiological effects of the 
enzyme on RBF.  Finally, I determined a functional role for the second messenger NAADP 
in mediating NE- and ET-1-induced [Ca2+]i responses in renal afferent arterioles.  These 
findings contribute greatly to the current understanding of RBF regulation and provide the 
groundwork for future studies characterizing the physiological effects of this pathway in 
health and disease and are summarized in figure 6.1. 
[Ca2+]i regulation in VSMC and endothelial cells contributes importantly to overall 
vessel tone and regulation of local tissue perfusion.  In the renal vasculature, alterations in 
[Ca2+]i of these cells and concurrent changes in contractile state of pre and postglomerular 
resistance arterioles influence RBF and GFR, leading to alterations in salt and water 
excretion and ultimately blood volume and blood pressure.  Thus, afferent and efferent 
arteriolar [Ca2+]i signaling can produce systemic hypertension and kidney disease.  The 
purpose of this dissertation was to investigate a novel Ca2+ signaling pathway involved in the 
regulation of renal vascular tone.  While previous work has lead to the discovery of a 
plethora of plasma membrane Ca2+ channels in VSMC and endothelial cells, I chose to 
83 
 
investigate a newly discovered enzyme system, ADPR cyclase, capable of generating two 
second messengers involved in mobilization of Ca2+ from intracellular stores in VSMC. 
 Prior to the start of this dissertation, little was known about the presence of ADPR 
cyclase in renal resistance arterioles.  In fact, only two publications existed:  one 
demonstrating production of the second messenger cADPR in renal microvessels  and its 
ability to increase [Ca2+]i  in VSMC (150) and a second showing attenuated [Ca2+]i responses 
to the vasoconstrictor Ang II in isolated renal afferent arterioles in the presence of inhibitors 
of ADPR cyclase, cADPR, and RyR (61).  Based on this information, I began to address the 
question of the significance of ADPR cyclase in the renal vasculature by performing in vivo 
studies aimed at testing whether ADPR cyclase and the downstream target of both second 
messengers produced by the enzyme, RyR perform a physiological role in the renal 
vasculature to regulate RBF.  Measurements of RBF in anesthetized Sprague-Dawley rats 
showed functional RyR as evidenced by vasoconstrictor responses to Ca2+ mobilization 
secondary to RyR opening by FK506, an agent that removes inhibitory FK506 binding 
proteins.  Vasodilatory responses to ADPR cyclase inhibition by nicotinamide led to the 
conclusion that ADPR cyclase activity contributes to the regulation of basal renal vascular 
tone under resting conditions. 
 Renal vascular tone in vivo is largely determined by local paracrine / autacrine factors 
and GPCR agonists.  As a result, my subsequent studies asked whether ADPR cyclase and 
RyR participate in downstream in vivo renal vasoconstriction by three common 
vasoconstrictors:  Ang II, NE, and ET-1.  Renal vasoconstrictor responses to Ang II and NE 
were attenuated during ADPR cyclase or RyR inhibition in anesthetized rats, implicating 
cADPR and/or NAADP production or activity downstream of AT1 and α1 adrenergic 
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receptors.  While AT1 is the primary contractile Ang II receptor in the renal vasculature (222) 
and NE likely works almost exclusively by α1 adrenergic receptor activation (209), ET-1 
produces renal vasoconstriction by acting on both ETA and ETB receptor subtypes (129).  For 
this reason, I used a combination of ETA and ETB receptor agonists and antagonists to 
analyze individual effects of ADPR cyclase and RyR inhibition on ET receptor subtypes.  
Interestingly, I found inhibition of both ETA and ETB receptor-induced renal vasoconstriction 
during ADPR cyclase or RyR inhibition, suggesting involvement of ADPR cyclase signaling 
pathways downstream of both receptor subtypes in renal VSMC. 
 While the cardiovascular importance of ADPR cyclase is only beginning to be 
elucidated,  biochemical studies of the enzyme led to extensive characterization of two 
mammalian ADPR cyclase family members:  CD38 and CD157 (BST-1) (224), both well-
known antigens presented on a variety of immune cell types.  As a result, while 
immunological and biochemical studies often differentiate between the two family members, 
cardiovascular studies tend to focus on ADPR cyclases in general.  CD38 often has greater 
expression and activity levels than CD157.  However, few studies have determined the 
expression or action of specific ADPR cyclases in any blood vessel.  Thus, I next sought to 
examine expression levels of both ADPR cyclases in renal microvessels.  To accomplish this, 
I used an iron oxide and sieving preparation to isolate preglomerular resistance arterioles 
from wild type C57black6 mice and expression levels of CD38 and CD157 mRNA were 
measured by real time quantitative RT-PCR.  mRNA of both ADPR cyclases was expressed 
in wild type tissues.  To determine whether knockout of CD38 increased CD157, I compared 
expression between wild type and CD38-/- strains.  Surprisingly, CD157 mRNA wa
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decreased, rather than increased, indicating a lack of upregulation of CD157 in the absence of 
CD38. 
 To ask whether CD38 is the primary ADPR cyclase regulating renal vascular 
reactivity to Ang II, NE, and ET-1, responses to these agonists were compared between wild 
type and CD38-/- mice.  Animals lacking CD38 produced consistently weaker RBF 
responses to GPCR stimulation.  The ADPR cyclase inhibitor nicotinamide, which almost 
completely abolished Ang II-induced renal vasoconstriction in wild type mice, had no 
significant effect on Ang II responses in CD38-/- animals.  Nicotinamide is a byproduct 
produced by all ADPR cyclases and therefore should equally inhibit all members of this 
family.  The fact that nicotinamide exerted no inhibitory action in CD38-/- mice strongly 
suggests that, while CD157 is detectable in renal preglomerular resistance arterioles, it is 
unlikely that this ADPR cyclase contributes significantly to Ang II-induced renal 
vasoconstriction. 
 While the bulk of my dissertation research has focused on ADPR cyclase and RyR 
with little emphasis on the second messengers produced in between, my final experiments 
addressed  the question of which metabolites mediate [Ca2+]i responses to the 
vasoconstrictors tested in previous studies.  Considerable work has focused on production of 
one metabolite, cADPR, both in renal and extrarenal vascular beds as well as the in vitro 
importance of this second messenger in mediating [Ca2+]i responses to a variety of GPCR 
agonists.  Very little effort, on the other hand, has focused on the role of NAADP in such 
processes and no single study existed examining the effects of NAADP in the renal 
vasculature.  Therefore, my final experiments were designed to determine the possible 
involvement of NAADP in renal afferent arteriolar [Ca2+]i signaling.  While all of my 
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previous experiments were performed in vivo to gain understanding of the overall 
coordination of the integrated physiological processes opposing and cooperating with each 
other to produce renal vasoconstrictor responses, the lack of knowledge in this specific area 
led me to choose to investigate [Ca2+]i responses in afferent arteriolar VSMC using intact 
isolated afferent arterioles without functioning endothelium.  Biochemical studies as well as 
studies in other isolated cells have shown that ADPR cyclase produces NAADP only at very 
low pH, such as that found in a lysosome (1) and that NAADP releases Ca2+ from lysosomes 
near RyR on the SR (135).  As a result, my study asked two questions:  whether lysosomal 
vesicle Ca2+ stores participate in GPCR-induced afferent arteriolar [Ca2+]i responses and 
whether NAADP acts downstream of these vasoconstrictors.  I found attenuated [Ca2+]i  
responses to NE and ET-1 in the presence of either lysosomal disruption with Concanamycin 
A and Bafilomycin A1 or inhibition of NAADP receptor with Ned-19.  These results indicate 
involvement of both lysosomes and NAADP in GPCR signaling pathways of afferent 
arterioles.  NAADP therefore likely contributes to NE and ET-1 signaling in renal afferent 
arterioles, an observation that opens the door for future investigation.  
B.  INTRACELLULAR MECHANISMS REGULATING Ca2+ MOBILIZATION IN 
AFFERENT ARTERIOLAR VSMC 
 My dissertation focused almost exclusively on Ca2+ mobilization from intracellular 
stores.  Nevertheless, extracellular Ca2+ has long been known to contribute importantly to 
changes in renal afferent and efferent arteriolar VSMC (236).  A wide variety of channels 
exist on VSMC plasma membranes to allow for Ca2+ entry.  L-type, T-type, and P/Q-type 
voltage-gated Ca2+ entry channels have all been identified in renal VSMC (70; 123; 58).  
Depolarization stimulated by GPCR agonists leads to activation of these channels.  In 
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addition, receptor-operated channels lie directly downstream of GPCR agonists (237; 56) and 
store-operated channels open in response to depletion of SR stores by GPCR agonists (58; 
257).   
Despite the prevalence of these channels, early research on Ca2+ release from internal 
stores suggested an alternative pathway dependent on phospholipase C (236) and IP3.  SR 
mobilization in renal VSMC was first thought to occur solely on IP3 production and 
stimulation of IP3R on the SR.  While ET-1 and NE induced such mobilization, it was 
thought that Ang II acted  preferentially through Ca2+ entry and almost independent of 
mobilization pathways (236; 208).  We now know that IP3-mediated Ca2+ mobilization 
actually contributes importantly to Ca2+ responses elicited by Ang II in renal afferent 
arterioles (61).   
 In addition to IP3R, RyR exist on SR membranes and contribute importantly to the 
amplification of Ca2+ responses by CICR in cardiac and skeletal muscle.  Only just before I 
began my dissertation did evidence emerge for function of RyR in renal VSMC including 
renal resistance arterioles (61; 150).  These studies showed ADPR cyclase and RyR 
participating in Ca2+ responses in isolated afferent arterioles.  I expanded this knowledge by 
demonstrating that Ang II and ET-1 work by actions on ADPR cyclase and RyR in vivo.  In 
addition, my in vivo animal experiments helped clarify functional importance and related 
issues beyond those addressed in isolated vessels.  I observed increases in basal RBF in 
response to ADPR cyclase inhibition, implicating, for the first time, regulation of basal Ca2+ 
levels by ADPR cyclase and RyR in renal VSMC under resting conditions.  One can 
speculate that these effects are due largely to basal production of cADPR known to sensitize 
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RyR, however, this hypothesis has not been tested in a systematic manner and thus awaits 
future experimentation. 
 My data also are novel in that they are the first to indicate that CD38 is the key ADPR 
cyclase participating in Ca2+ responses to Ang II, NE, and ET-1 in the renal microcirculation.  
The experiments were all done in vivo, and future experiments examining Ca2+ responses in 
isolated afferent arterioles of CD38-/- mice would document effects of CD38 deletion on 
afferent arteriolar [Ca2+]i.   
 In addition to SR stores, high [Ca2+] is maintained in mitochondria and lysosomes 
(135; 95).  Although [Ca2+] is high in these organelles, its pool is significantly smaller than 
that in extracellular or SR stores and, for this reason, it has long been assumed that these 
stores do not significantly contribute to global [Ca2+]i responses in VSMC.  At present, my 
data  are the only information  available showing a contribution of lysosomal vesicle stores to 
global [Ca2+]i responses to any agonist in any resistance arteriole.  Specifically, my findings 
implicate that this Ca2+ exits lysosomes through NAADP receptors sensitive to Ned-19.  
Publications on pulmonary arterial VSMC suggest that NAADP receptors are coupled to 
RyR, but experiments are needed to show whether this is the case in afferent arterioles.  
Indeed, future studies should focus on determining whether this is the only path for 
lysosomal vesicle Ca2+ in afferent arterioles and whether this path is similar or different from 
that observed in VSMC from other vascular beds. 
 My studies indicate an extremely important effect of ADPR cyclase and NAADP on 
in vivo and in vitro afferent arteriolar [Ca2+]i responses to a variety of GPCR agonists.  It is 
noteworthy that other studies have seen large effects of inhibition of Ca2+ entry (193) and IP3 
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receptors (65) on ET-1-induced afferent arteriolar [Ca2+]i responses.  It is therefore likely that 
a considerable amount of crosstalk exists between the various pathways.  My data suggest at 
least one type of crosstalk:  that L-type channel responses are amplified by the actions of 
ADPR cyclase and RyR.  However, other types of intereactions must be involved to explain 
the large degree of inhibition seen during blockade of NAADP receptors, IP3 receptors, RyR, 
and various plasma membrane Ca2+ channels independent of one another.  An extensive set 
of studies is required to investigate crosstalk among pathways in VSMC in general and 
specifically in afferent arterioles. 
C.  PHYSIOLOGICAL IMPACT OF VSMC Ca2+ MOBILIZATION ON RENAL 
HEMODYNAMICS 
 Ca2+ plays a fundamental role in regulating in vivo renal vascular tone both through 
VSMC and endothelial cells.   Increases in [Ca2+]i in EC lead to eNOS activation and vessel 
dilation whereas activation of similar pathways (i.e. mobilization by IP3R and RyR) in 
VSMC produce vessel contraction.  As a result, it is difficult to predict overall physiological 
effects of pathways that increase [Ca2+]i in both cell types, and the study of integrated renal 
vascular responses is extremely important.  On the other hand, the complexity of integrated 
responses means that physiological studies may not always reveal the intricacies of Ca2+ 
signaling pathways.  As a result, it is useful to consider in vitro preparations as well.  The 
simplest preparation (in terms of data interperetation) is isolation of a single cell type, 
cultured VSMC of preglomerular resistance arterioles.  These arterioles are isolated using the 
iron oxide/sieving method, and VSMC grown in culture conditions that provide 
overwhelmingly slower growth of endothelial cells (278; 197).  The result is a pure, stable, 
primary culture that does not require the sacrifice of many animals.  However, there are 
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limitations.  For example, expression of some proteins (189) changes over time in culture.  
Certain receptors and signaling pathways may change in these artificial conditions.  For this 
reason, we believe it is advantageous to study freshly isolated over cultured cells.  Even 
closer to the in vivo setting, but still in a controllable environment are intact vessel segments 
where isolated afferent arterioles can be studied.  The benefits of this VSMC preparation 
include the absence of functioning endothelial cells (65) and selective identification of 
afferent arterioles in a reproducible controllable environment.  In addition to relevance, 
freshly isolated arteriolar segments and their VSMC are attractive for initial studies for these 
reasons as well as the low concentration of reagents required.  Thus, I chose this preparation 
for my in vitro studies of Ca2+ signaling and NAADP receptors.  Future studies are required 
to determine the physiological role of NAADP receptors and lysosmal vesicles in the 
regulation of integrated renal vascular responses in vivo. 
For the majority of my studies of vascular contraction and reactivity in vivo, I 
performed whole animal surgeries on either rats or mice.  My initial RBF studies 
investigating the use of ADPR cyclase and RyR inhibitors in vivo were conducted in parallel 
to in vitro Ca2+ signaling studies on isolated afferent arterioles (65; 61; 66).  In almost all 
cases, the in vivo and in vitro data agree.  An exception of my in vivo studies is the finding of 
the importance of ADPR cyclase and RyR in both ETA and ETB receptor subtype signaling in 
RBF experiments, as compared to primary mediation of ETB receptor actions in isolated 
afferent arterioles.  It is not known whether the ETB receptor is more labile and may have 
been disrupted during isolation or whether this difference reflects interactions between ETA 
and ETB receptor subtypes not present in isolated vessels. The exact nature of ET receptor 
interactions in vivo is only beginning to be investigated and it is therefore difficult to guess 
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as to the specific action present in vivo vs. in vitro (129; 18).    Future experiments should 
explore ET receptor subtype interactions in the renal vasculature and the effect of these 
interactions on ADPR cyclase activation. 
 My in vivo studies provide new information demonstrating basal and agonist-induced 
physiological actions of ADPR cyclase and RyR in the renal microcirculation.  I also show 
that the bulk of the actions of ADPR cyclase inhibition occur through effects on the ADPR 
cyclase CD38.  It is important to note that biochemical and genetic characterization of ADPR 
cyclase family members is in its infancy.  It has been suggested that subpopulations of ADPR 
cyclases exist such as cytosolic ADPR cyclase (38) and a specific vascular ADPR cyclase 
(50; 64).   Characterization of these enzymes as CD38, CD157, or a novel family member 
remains to be seen.  My studies were by design therefore limited to CD38 and CD157 and, 
due to the unavailability of CD157 knockout animals, were largely focused on CD38.  My 
experiments convincingly demonstrate the absence of effect of ADPR cyclase inhibition in 
CD38-/- animals and suggest predominance of CD38 in integrated renal vascular responses, 
an effect of other family members cannot be excluded.  As new data emerge further 
characterizing this family, the role of various members in renal vasoconstrictor responses in 
vivo should/could be investigated. 
D.  IMPLICATIONS FOR HEALTH AND DISEASE 
 Renal afferent arterioles are known to participate in the pathogenesis of several 
diseases including hypertension and kidney disease.  The contractile state of these vessels 
determines RBF, GFR, glomerular capillary pressure and post-glomerular capillary pressures.  
Decreases in RBF and GFR due to enhanced afferent arteriolar contraction can lead to salt 
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and water retention and an increase in blood volume.  This increase in blood volume can, 
over time, produce hypertension.  High arterial pressure can, in turn, depending on the 
efficiency of preglomerular autoregulatory mechanisms, lead to glomerular injury and kidney 
disease.  Although the exact mechanisms underlying the increase in total peripheral vascular 
resistance associated with hypertension are not completely known, our current understanding 
suggests that alterations in downstream pathways of common renal vasoconstrictors 
contribute.  This idea is evidenced by the fact that spontaneously hypertensive rats (SHR), a 
strain selectively bred for high blood pressure as a model of essential hypertension in 
humans, have increased renal vascular reactivity to many vasoconstrictors including Ang II 
(31), NE (177), and ET-1 (86), AVP (68), thromboxane (31) and reduced responses to 
vasodilators such a prostaglandins and dopamine (32).  It is for this reason that the 
constrictors Ang II, ET-1 and NE were chosen for use in this dissertation. 
 In summary, my dissertation research sheds new light on signaling pathways 
downstream of GPCR of common renal vasoconstrictors and provides compelling evidence 
for an important role of the ADPR cyclase/RyR signaling pathway in mediating acute 
constrictor effects of Ang II, NE, and ET-1 in normotensive animals.  While my research 
provides essential basic knowledge regarding these pathways in health, it remains to be seen 
whether exaggerated activity of the ADPR cyclase/RyR pathway participates in the 
development or maintenance of cardiovascular diseases such as hypertension.  Future 
experiments could compare the effects of acute and chronic pharmacological ADPR cyclase 
inhibition in SHR and normotensive rats.  Also of interest would be the ability of Ang II 
infusion and/or high salt diet to produce hypertension in CD38-/- mice vs. wild type controls.  
Such experiments should help determine the contribution of this newly discovered signaling 
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pathway to cardiovascular disease and hypertension and may help pave the way for the 
discovery of novel antihypertensive therapies. 
  
  
 
 
Figure 6.1.  ADPR cyclase activation leads to 
production of cADPR and/or NAADP.  In renal microvessels, ADPR cyclase functions 
basally to enhance Ca2+ entry by L
activated downstream of GPCR agonists.
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stimulation and/or sensitization of RyR via 
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